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ABSTRACT OF THE DISSERTATION
The Hematopoietic Compartment Regulates Osteoblast Differentiation and
Apoptosis during Cytokine Treatment
by
Matthew John Christopher
Doctor of Philosophy in Biology and Biomedical Sciences
(Molecular Cell Biology)
Washington University in St. Louis, 2010
Professor Daniel Link, MD., Chairperson

Adult hematopoiesis normally occurs in bone marrow, where hematopoietic stem cells
(HSC) reside within a specialized microenvironment. At steady state, hematopoiesis
state is regulated such that immature hematopoietic stem and progenitor cells (HSPC) are
restricted to the bone marrow and are rarely observed in peripheral blood. Under certain
circumstances, however, this regulation is loosened and significant numbers of HSPC are
released to the circulation, a process termed “mobilization.” Mobilization can be induced
pharmacologically by a wide range of agents. Of these, the best characterized and most
widely used mobilizing agent is Granulocyte-colony stimulating factor (G-CSF). G-CSF
is widely used clinically and several molecular mechanisms have been
implicated as mediating its mobilizing action. However, many questions remain
as to the relationship between these various pathways. This work begins by
focusing on one mobilization pathway, the disruption by G-CSF of signaling
between CXCL12, a chemokine expressed in the HSC microenvironment, and its
receptor CXCR4, broadly expressed on hematopoietic cells. By examining mice

x

genetically deficient in CXCR4, we show that this mechanism is not only the
predominant pathway by which G-CSF induces mobilization, but also a common
pathway utilized during treatment with other hematopoietic cytokines. Next,
while investigating the mechanism by which G-CSF disrupts CXCL12/CXCR4
signaling, we unexpectedly uncovered a role for osteoblasts in regulating
cytokine-induced mobilization. By isolating and sorting different fractions of
bone marrow stromal cells we demonstrate that osteoblasts represent a major
source of CXCL12 in the bone marrow. In addition, both the number and
function of mature osteoblasts declines sharply during cytokine treatment.
Subsequent analysis demonstrated that G-CSF both increases the rate of
osteoblast apoptosis and blocks osteoblast development. Finally, experiments
with G-CSF receptor null chimeras demonstrate that this effect on osteoblasts is
not direct but is mediated by the hematopoietic compartment. While the
regulation of hematopoiesis by osteoblasts has been well described, the
reciprocal regulation of osteoblasts by bone marrow hematopoietic cells has not
been widely appreciated. Further work will be required to determine if this
regulation occurs not only during the specialized setting of cytokine-induced
mobilization but during steady state hematopoiesis in general.

xi

CHAPTER 1

INTRODUCTION

1

1.1 Introduction
Adult hematopoiesis normally occurs in bone marrow, where hematopoietic stem cells
(HSC) reside. This small pool of slow-cycling cells can differentiate into highly
proliferating committed progenitors of any hematopoietic lineage according to the needs
of the host. As these progenitors differentiate into mature hematopoietic cells, they are
released into the circulation to meet the host’s need for oxygen transport, hemostasis, and
innate and adaptive immunity. The hierarchical organization of hematopoiesis serves to
protect the genomic integrity of the stem cell pool while retaining a proliferative potential
capable of releasing billions of mature hematopoietic cells into circulation each day. Not
surprisingly, then, the localization of HSC within their specialized bone marrow
microenvironment and the subsequent release of their mature progeny into circulation are
ordinarily tightly regulated.
During periods of stress or injury, however, this strict regulation is loosened, and HSC
and other primitive hematopoietic progenitors—collectively termed “HPSC”—are
released from the bone marrow, a process termed “mobilization”. Conversely, HSC
delivered intravenously after myoablative conditioning home from the circulation back to
the bone marrow where they reconstitute recipient hematopoiesis.
The discovery in the 1990s that pharmacologic doses of hematopoietic cytokines
mobilize HSC to the peripheral blood without harming the subject spurred research into
the clinical feasibility of using mobilized peripheral blood HSC in stem cell transplants.
1,2

Mutiple clinical trials showed cytokine-mobilized peripheral blood stem cells to be an

effective and cost-efficient source of cells for stem cell transplant.3-6 Currently, the
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majority of therapeutic stem cell transplants worldwide utilize mobilized peripheral blood
HSC.7,8
Despite the wide clinical use of mobilized HSC, much about the mechanisms
underlying HSPC mobilization remains unclear. The purpose of this work is to elucidate
mechanisms by which HSPC are retained in the supportive bone marrow environment at
steady state and are induced to migrate to the circulation during mobilization. It is hoped
that a more precise understanding of these pathways will lead not only to improved
protocols for HSC mobilization and collection in the transplant setting, but also to new
insights into the manner in which HSPC are maintained in the bone marrow.

1.2 Hematopoietic stem cells reside within specialized “niches” in the bone marrow.
In the strictest sense of the term, a stem cell niche is a specialized microenvironment
comprised of supporting cells and extracellular matrix where stem cells reside and
receive signals necessary for their maintenance as stem cells. In Drosophila ovarioles,
for example, a germline stem cell niche is provided by somatic cap cells which provide
signals necessary to maintain the critical balance between germ stem cell self renewal
and differentiation.9
Although the existence of a niche for HSC was first proposed by Schofield in 1978 10,
its anatomical location has remained unknown until relatively recently. Early studies
revealed that primitive CFU-C and CFU-S increase in frequency closer to the endosteal
surface in long bones.11,12 Similarly, Nilsson et al. showed that sorted bone marrow
populations enriched for stem cell activity (Rho123 low, lineage negative) preferentially
homed to endosteal regions.13 These observations raised the possibility that endosteum-
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lining osteoblasts or osteoblast-lineage cells contribute to the stem cell niche. In vitro,
osteoblasts abundantly express hematopoietic cytokines G-CSF, GM-CSF, and IL-6.
Cultured osteoblasts support the maintenance of primitive hematopoietic cells as
determined by CFU-C and LTC-IC assays.14,15 Recent evidence has suggested that
osteoblasts play a key role in supporting the stem cell niche in vivo, as well. Calvi et al
reported that transgenic expression of a constitutively active form of the parathyroid
hormone receptor (caPRP) under control of a 2.3kb fragment from the col1a1 locus
significantly expanded the osteoblast compartment as measured by standard
histomorphometric techniques. This increase in osteoblast number was associated with a
roughtly 2-fold increase in number of LTC-IC and in donor chimerism in a competitive
repopulation assay, suggesting an increase in HSC number or function.16 In a similar
system, Zhang et al. expanded the osteoblast compartment by deleting the bone
morphogenic protein receptor gene bmpr1a in non-hematopoietic cells. Similar to the
results in Calvi et al., the increase in osteoblast number and trabecular bone was
associated with a 2.2-fold increase in number of HSC as determined by limiting dilution
assay.17
In the converse experiment, Visnjic et al. generated a transgenic mouse expressing the
thymidine kinase suicide gene under control of the col1a1 2.3kb promoter. Four week
treatment with gancyclovir resulted in a striking loss of mature osteoblasts and trabecular
bone. Hematopoiesis in bone marrow was severely compromised, with a 5-10-fold
decrease in cellularity, a 3-10-fold decrease in primitive c-Kit positive, Sca-1 positive,
lineage negative (KSL) cells, and extensive extramedullary hematopoiesis.18
Collectively, these studies suggest that the size of the HSC pool relates directly to the
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osteoblast compartment, consistent with the possibility that osteoblasts play an important
role in the HSC niche.
Much study has been given recently to understanding the molecular signals by which
osteoblasts might regulate HSC. Osteoblasts express the adhesion molecule VCAM-1
and the chemokine Stromal-derived factor 1 (SDF-1/CXCL12), which play a role in HSC
retention in the marrow (see below).19-21 Calvi et al. observed enhanced osteoblast
expression of Notch ligand Jagged-1 in their caPRP transgenic mice, and inhibitors of
Notch signaling abrogate the enhanced LTC-IC numbers in their model, suggesting that
Notch signaling contributes to HSC support in the osteoblastic niche.16 In a different
study, quiescence in HSC was identified with Tie-2 expression, and Tie-2 positive HSC
were identified along endosteal surfaces. Tie-2 ligand angiopoietin 1 (Ang-1), which is
expressed by osteoblasts, promoted maintenance of HSC quiescence and preserved longterm repopulating ability in ex vivo cultured HSC.22 Osteoblasts also express several
wingless (Wnt) family members, which have been implicated as important paracrine
factors in maintaining the HSC pool.23,24
Besides factors expressed by osteoblasts, certain properties of the endosteal niche may
contribute to HSC maintenance. Oxygen tension along the endosteal surface is lower
than in the bone marrow proper, which might serve to lower the risk of HSC sustaining
oxidative damage,25 and HSC cultured in low oxygen conditions retain their repopulating
activity better than HSC cultured in normoxia.26 Similarly, local calcium ion
concentrations along the endosteal surface are much higher than elsewhere in the bone
marrow.27 Lack of CaR, a calcium-sensing G-protein-coupled receptor expressed on
HSC, leads to loss of HSC in the bone marrow, suggesting that the local calcium ion
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concentration along the endosteal surface might contribute to HSC support.28 Taken
together, these findings suggest an important role for osteoblast-lineage cells in
supporting HSC along bone marrow endosteal surfaces.
Despite the above-mentioned findings, the precise characterization of the HSCsupporting osteoblast population remains unclear. Zhang et al. show that slow-cycling,
hematopoietic cells found along endosteal surfaces were localized near N-cadherin
positive, spindle shaped bone lining cells (SNO cells), raising the possibility that this
subset of osteoblastic cells defines the stem cell niche. Likewise, it is possible that other
stromal components contribute to the stem cell niche. For example, Sugiyama et al. have
identified a population of reticular stromal cells that localize near endosteal surfaces as
well as elsewhere in the marrow. These cells, termed “CAR” cells (CXCL12-abundant
reticular cells), express high levels of SDF-1, raising the possibility that they contribute
to HSC maintenance in the bone marrow.29
Besides an endosteal stem cell niche, some evidence suggests that specialized bone
marrow endothelium provides an additional niche for HSC. Recent advances in
technology have allowed for identification of cell populations highly enriched for HSC.
Kiel et al. showed that roughly half of CD150 positive, CD48 negative cells (SLAM
cells) are true stem cells.30 Surprisingly, immunofluorescent imaging localized only a
small fraction of this population to the endosteal surface. The majority of SLAM cells
were shown in the bone marrow adjacent to bone marrow sinusoids, suggesting that bone
marrow endothelial cells may constitute a second HSC niche. In contrast, Sugiyama et
al. showed SLAM cells localized to endothelial-associated CAR cells rather than to
endothelium itself.29 Despite these findings, there is currently no data linking
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endothelial or CAR cells to HSC function. However, Sacchetti et al. showed that human
reticular adventitial cells located adjacent to endothelium and expressing CD146 were
necessary and sufficient to form ectopic bone when xenotransplanted into
immunocompromise mice. This ectopic bone was colonized by hematopoietic cells,
suggesting that these endothelium-associated CD146 positive cells may functionally
support stem cells in vivo.31
In summary, the support of resident non-hematopoietic cells is critical for the
maintenance of HSC in the bone marrow. In particular, osteoblasts fulfill the criteria for
stem cell niche-defining cells in that their expansion results in increased HSC numbers
and their ablation causes loss of hematopoiesis in the bone marrow. The observation that
HSC localize to areas other then endosteal surfaces suggests, however, that HSC may
reside in more than one niche and may indeed traffic between niches. Interestingly,
despite their need to reside in a niche for long-term functioning, under certain
circumstances HSC are observed to leave their bone marrow niche and are released to the
circulation.

1.3 Mobilization of HSC from the bone marrow niche.
As described above, the release of hematopoietic cells from the bone marrow is tightly
regulated to ensure that immature cells are retained in the bone marrow. Nevertheless, it
has long been appreciated that low numbers of hematopoietic stem and progenitor cells
(HSPC) can, in fact, be observed in the circulation.32,33
Whether these circulating HSPC serve a teleological function is unknown.
Experiments in parabiotically joined mice demonstrate that circulating HSPC are able to
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colonize distant sites, leading to speculation that circulating progenitors aid recovery
from injury or infection.34 Recent evidence for this hypothesis was provided by
Massberg, et al. who showed that circulating HSPC can proliferate and differentiate into
dendritic cells within peripheral organs in response to stimulation by Toll-like receptor
agonists.35 At baseline, these circulating HSPC are extremely low in number, estimated
100-400 per mouse.36 However, a wide range of physiologic and pharmacologic
stimuli—including bone marrow stress, hypoxia, infection, and cytotoxic drugs—can
significantly increase the number of circulating HSPC, lending further credibility to the
hypothesis that circulating HSPC aid recovery from injury (reviewed in 37).
Mobilization can be induced by a wide variety of pharmacologic agents, including
chemokines, cytokines, and cytotoxic drugs (see table 1). Besides these three broad
classes, however, a surprisingly diverse list of mobilizing agents is accumulating. These
include such disparate molecules as lipopolysachharide (LPS) and fucoidan, a sulfated
polysaccharide isolated from seaweed.38-40 As the molecular underpinnings of
mobilization are elucidated, a second generation of mobilizing agents are being designed
to activate specific mobilizing pathways. For example, AMD3100, a small molecule
inhibitor of CXCR4, has been studied extensively in animal models and has undergone
phase I clinical trials in both autologous and allogeneic settings.41-43
Mobilizing agents exhibit considerable diversity both in their presumed molecular
targets as well as their kinetics, which range from 15-30 minutes to peak mobilization in
the case of chemokines to greater than 5 days in the case of hematopoietic cytokines.
Given this diversity, it is likely that multiple mechanisms exist for the mobilization of

8

hematopoietic progenitors. At the same time, the possibility remains that at least certain
subsets of mobilizing agents may share common pathways.
Mobilizing Agent
G-CSF
GM-CSF
Flt-3 ligand
Stem Cell Factor
VEGF
Cyclophosphamide
MIP1α
Groβ
Fucoidan
LPS
Pertussis Toxin
AMD3100
Intense Exercise

Mobilization
20-100-fold increase
45-fold increase
500-fold increase
20-fold increase
10-fold increase
62-fold increase
5-10-fold increase
5-10-fold increase
7-30-fold increase
8-fold
10-20-fold
5-fold
4-fold

Time to peak response
7-14 days
7 days
7 days
7-10 days
5 days
8 days
15-30 minutes
15-30 minutes
30min-2 hr
5 days
3-4 days
1 hr
n.a.

Reference
44,45
46,47
48-50
47,51
52
53,54
55,56
57
38
39,40,58
59
43

Table 1.1.
Parial list of
mobilizing
agents
[adapted
from
Thomas et
al. Current
opinion in
hematology
(2002)]

60,61

Although both G-CSF and GM-CSF are currently approved for clinical use, the best
studied and most widely used mobilizing agent is G-CSF. As will be discussed below,
three general mechanisms have been implicated in mediating G-CSF-induced
mobilization: 1) induction of bone marrow proteases, which are believed to cleave ECM
and degrade key signaling molecules; 2) downregulation of adhesion molecules that
maintain HSPC in the bone marrow at steady state; and 3) disruption of SDF-1/CXCR4
signaling, which is thought to signal to retain HSPC in the bone marrow.

1.4 Induction of proteases is a common motif in HSPC mobilization.
Treatment with G-CSF dramatically increases the myeloid content of the bone marrow
along with a corresponding increase in the activity of neutrophil-derived serine proteases
neutrophil elastase (NE) and cathepsin G (CG) as well as metalloproteinase 9 (MMP9).62
Additionally, bone marrow expression of serpin family protease inhibitors decreases,
resulting in the induction of a proteolytic bone marrow environment.63 Proteolytic
cleavage of ECM may facilitate HSPC migration from the extramedullary space to the
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circulation. Also, enhanced protease activity might promote cleavage of adhesion
molecules that tether HSPC to their stromal environment and degrade critical signaling
molecules to facilitate HSPC mobilization. In support of this model, bone marrow
extracts from treated mice have been shown to cleave the VCAM-1 adhesion molecule as
well as chemokine SDF-1 and its receptor CXCR4.64-66 Furthermore, MMP-9 can cleave
in vitro the tyrosine-kinase receptor c-Kit which is expressed on HSPC.67 Treating mice
with inhibitors to NE or both NE and CG inhibited G-CSF-induced HSPC mobilization,
and mobilization was blunted 40-50% in mice treated with anti-MMP9 neutralizing
antibody.66,68 These findings, however, contrast with other data showing that G-CSFinduced mobilization is unaffected in NE knockout mice, NE x CG knockout mice,
MMP-9 knockout mice, and DPP1 knockout mice which are unable to activate neutrophil
serine proteases in general.69 Possible explanations for this discrepancy include the
developmental adaptation of mice deficient from birth in certain proteases or the
difference in strains used in these studies. Nevertheless, there currently exists no genetic
evidence that neutrophil proteases play a role in G-CSF-induced mobilization.
Similar to G-CSF, there is evidence that protease upregulation plays a role in
chemokine-induced mobilization. Treatment with CXCR2 ligands Groβ and IL8 increase
plasma and bone marrow levels of MMP9, and treatment with neutralizing antibody
against MMP9 or the broad-spectrum protease inhibitor serpin 1a/α1 antitrypsin blocked
IL8-induced mobilization.68,70,71 Curiously, while Groβ treatment mobilizes poorly in
MMP9 deficient mice, IL8 mobilization occurs normally.68,71
The implication of neutrophil proteases in chemokine-induced mobilization, along
with the observation that neutrophils are activated both by chemokines and G-CSF, has
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led to the hypothesis that neutrophils play a key role in mobilization.72,73 Indeed,
peripheral neutropenias induced either by clearance with an antibody against Gr-1 or
genetically in G-CSF receptor deficient mice prevents mobilization with IL-8.71,74 The
role of peripheral blood neutrophils is less clear in G-CSF-induced mobilization,
however, as mixed G-CSFR knockout and wildtype bone marrow chimeras mobilize
poorly with G-CSF despite having a normal complement of wild type neutrophils in
circulation. (Link DC, unpublished data)

1.5 Adhesion molecules mediate HSPC retention in the bone marrow
microenvironment.
The trafficking of HSPC from their local bone marrow microenvironment and release
into circulation is thought to involve downregulation of adhesion molecules that normally
govern interaction between HSPC and their local stromal and ECM elements.
Hematopoietic cells widely express β1 and β2 integrins. β1 integrins VLA-4 and VLA-5
(α4β1 and α5β1) are expressed on bone marrow HSPC and their ligands are expressed on
stromal cells and bone marrow ECM. VLA-4 expression and activity are high in bone
marrow HSPC and decrease with differentiation. Given that HSPC are preferentially
retained in the bone marrow, this observation raises the possibility that VLA-4 in
particular may play a role in the release of mature hematopoietic cells during
mobilization.75,76 Indeed, treatment with anti-VLA5 antibody results in a modest HSPC
mobilization in mice, and anti-VLA-4 antibody causes robust HSPC mobilization in mice
and rhesus monkeys.77,78 Similarly, mice with an induced deletion of the gene encoding
α4 integrin have an elevated level of peripheral blood HSPC.79 Finally, neutralizing
antibody against vascular cell adhesion molecule 1 (VCAM-1), an immunoglobulin
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superfamily member and VLA-4 ligand present on stromal cells, mobilizes HSPC to a
similar extent as VLA-4 neutralization. Together, these findings suggest that VLA4/VCAM-1 specifically mediate a HSPC/stromal cell interaction that retains HSPC in the
bone marrow.

80

In contrast to the β1 integrins, whose neutralization leads to HSPC mobilization, β2
integrin neutralization does not result in elevated HSPC numbers in peripheral blood.
However, β2 integrin neutralization, either with neutralizing antibody or by genetic
deletion, results in enhanced mobilization with VLA-4 neutralization, suggesting that β2
integrins may co-operate with β1 integrins in maintaining HSPC in the bone marrow but
do not play a necessary role.78
Besides integrins, HSPC adhesion in the bone marrow microenvironment involves
CD44, the receptor for hyaluronan, a gycosaminoglycan component of the ECM.
Neutralizing antibodies against CD44 disrupt progenitor adhesion to fibronectin in vitro
and cause a modest mobilization of HSPC in vivo.81,82 On the other hand, CD44 null
mice treated with G-CSF have attenuated rather than enhanced mobilization, suggesting
that CD44 plays a more complex role than simply mediating HSPC retention to the bone
marrow.82

1.6 SDF-1/CXCR4 signaling maintains HSPC in their bone marrow niche.
In addition to the role played by proteases and adhesion molecules in mediating HSPC
mobilization, signaling between chemokine SDF-1 and its receptor CXCR4 has emerged
in recent years as a third major mechanism regulating HSPC trafficking. SDF-1
(CXCL12), a chemokine of the C-X-C family, was initially discovered in a screen of
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stromal cell line conditioned media as a chemoattractant for human CD34 positive
progenitor cells.83 Its primary receptor, CXCR4, is a G-protein-coupled seven
transmembrane chemokine receptor present on bone marrow hematopoietic cells as well
as neuronal, endothelial, and epithelial cells.84 Several lines of evidence suggest a model
wherein SDF-1, expressed by bone marrow stromal cells, signals to hematopoietic cells
through CXCR4 to cause their retention in the bone marrow.
First, genetic ablation of CXCR4 signaling impairs retention of HSPC in the bone
marrow. Mice deficient in either SDF-1 or CXCR4 die in late gestation with several
developmental defects, including a failure of hematopoietic cells to colonize the bone
marrow. SDF-1 knockout embryos have a high number of circulating hematopoietic
stem cells, however, suggesting either a failure to home or a failure to be retained in the
marrow. 85,86 CXCR4 null fetal liver cells do not engraft irradiated recipients efficiently
despite homing normally to the bone marrow, again suggesting a defect in retention.87
Resulting CXCR4 null chimeras have a high number of circulating HSPC.88 Conversely,
hypermorphic mutations in the CXCR4 gene that lead to enhanced signaling result in a
human disease characterized by a failure of myeloid cells to be released normally from
the bone marrow.89,90
Next, antagonism of CXCR4 signaling with AMD3100, a small molecule inhibitor,
leads to rapid release of HSPC to the peripheral blood.91 Continuous administration of
AMD3100 leads to sustained and robust HSPC mobilization.92 Similarly, administration
of proteoglycans fucoidan and dextran sulfate both lead to mobilization with an
concurrent reduction of bone marrow SDF-1.93
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Finally, as will be described later, mobilization of HSPC during G-CSF treatment is
associated with decrease of bone marrow SDF-1 protein and mRNA that mirrors the
kinetics of mobilization.21,66 At the same time, CXCR4 surface expression and signaling
decrease on mobilized progenitor cells compared to bone marrow HSPC, suggesting that
G-CSF-induced loss of CXCR4 on a subset of HSPC cells may synergize with loss of
bone marrow SDF-1 during mobilization.64
The downstream cellular mechanisms by which CXCR4 signaling promotes retention
in the bone marrow have not been fully elucidated. SDF-1 binding CXCR4 in human
CD34 positive cells activates multiple signaling pathways including phosphatidylinositol
3-kinase (PI3K), protein kinase C (PKC), and mitogen-activated protein kinases ERK-1
and -2. These events lead to tyrosine phosphorylation of focal adhesion components
related adhesion focal tyrosine kinase (RAFTK) and the cytoskeletal protein paxillin.
Subsequent cytoskeleton reorganization and cell migration can be blocked with small
molecule inhibitors to PI3K and PKC.94,95 However, it is not fully clear whether
hematopoietic progenitors remain in the bone marrow simply via chemotactic signaling
toward a gradient of SDF-1 produced by bone marrow stromal cells or whether other
cellular processes are involved. Incubation of HSPC with SDF-1 increased VLA-4
affinity for its ligands and enhanced endothelial transmigration in a VLA-4 and VLA-5dependent fashion in vitro, suggesting that SDF-1 signaling may promote HSPC retention
in the niche through regulation of adhesion molecules as well as providing a chemotactic
signal.96,97
In sum, these data suggest that the SDF-1/CXCR4 interaction is crucial for retention
of hematopoietic cells in the bone marrow and that disruption of that interaction leads to
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mobilization. How treatment with G-CSF and other mobilizing agents disrupt this
interaction, however, is a matter of ongoing investigation.

1.7 Disruption of SDF-1/CXCR4 signaling during mobilization.
During treatment with G-CSF, SDF-1 protein decreases in the bone marrow.
However, some controversy exists as to how this occurs. One hypothesis is that SDF-1
protein is degraded by bone marrow proteases. Christophersen et al. showed that CD26,
a cell-membrane-associated dipeptidyl peptidase, inactivates SDF-1 by cleaving its amino
terminal two residues.98 Indeed, mice deficient in CD26 have a less severe drop in bone
marrow SDF-1 and less robust mobilization in response to G-CSF.99 Expression of
CD26, however, does not change with G-CSF treatment, so while this mechanism may
function basally to clear SDF-1 from the marrow, it cannot account for the decrease
during G-CSF treatment.
In contrast to CD26, bone marrow levels of neutrophil-derived proteases NE, CG, and
MMP9 increase during G-CSF treatment. Bone marrow extracts from G-CSF-treated
mice cleave SDF-1 in vitro, which has led to the hypothesis that these proteases mediate
mobilization in part by degrading SDF-1.64,66 However, as noted above, mice deficient in
neutrophil serine proteases as well as mice treated with broad spectrum metalloproteinase
inhibitors mobilized normally,69 indicating that these specific proteases are not required
for SDF-1 degradation. Nevertheless, the great number and overlapping functions of
proteases makes it difficult to rule out a role for proteolytic cleavage of SDF-1 based on
knockout studies.
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Alternatively, it is possible that G-CSF treatment leads to a fall in bone marrow SDF-1
by decreasing its expression. As discussed in Chapter 2 of this thesis, G-CSF treatment
leads to a fall in total bone marrow SDF-1 mRNA with similar kinetics to the fall in SDF1 protein, suggesting that this may be the primary mechanism by which G-CSF targets
bone marrow SDF-1.21,100 Finally, outside the context of hematopoietic mobilization,
other studies have shown SDF-1 levels to be transcriptionally regulated.101-103
Notably, while downregulation of SDF-1 likely plays an important role in G-CSFinduced mobilization, it is unclear to what extent disruption of SDF-1/CXCR4 signaling
plays a role in mobilization induced by other mobilizing agents. No data has been
published examining the disruption SDF-1/CXCR4 signaling in bone marrow of mice
mobilized with other cytokines or with cytotoxic agents. The kinetics and extent of
mobilization induced by these agents, however, are similar to that of G-CSF and are
compatible with a role for SDF-1 downregulation. In contrast, chemokine induced
mobilization, which peaks within half an hour of chemokine administration, does not
likely involve a transcriptional downregulation of SDF-1, and indeed, mobilization
induced by the chemokine Groβ does not result in loss of bone marrow SDF-1.68
Nevertheless, the possibility remains that attenuated CXCR4 signaling may contribute to
mobilization induced by chemokine administration. One novel pathway by which this
may occur is heterologous desensitization, a phenomenon wherein CXCR4 signaling may
be blunted by activation of co-expressed cytokine receptors. A recent study showed that
treatment of neutrophils with the CXC chemokine KC led to heterologous desensitization
of CXCR4.104 This effect, however, is not observed with all chemokine receptors,
suggesting that downregulation of SDF-1/CXCR4 signaling is not the only mechanism
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leading to neutrophil release.105 Currently, however, there is no evidence for
heterologous desensitization of CXCR4 signaling playing a role in HSPC mobilization.
To summarize, G-CSF-induced mobilization is associated with a loss of SDF-1
protein and mRNA in the bone marrow. While proteolytic degradation may play a role in
SDF-1 degradation, the loss of SDF-1 mRNA suggests that G-CSF treatment targets
SDF-1 transcription in the stromal components of the stem cell niche during HSPC
mobilization. To understand how SDF-1 mRNA is downregulated during G-CSF
treatment, it is necessary to identify which bone marrow cell types produce SDF-1.

1.8 SDF-1-producing cells in the bone marrow.
The drop in SDF-1 mRNA in the bone marrow suggests that G-CSF targets one or
more SDF-1-producing cell populations in the bone marrow, leading to decreased SDF-1
mRNA. Some controversy exists regarding the exact identity of the populations that
express SDF-1, and it has not yet been shown if any of these downregulate SDF-1
expression during G-CSF treatment. In vitro, the literature reports SDF-1 expression in
immortalized stromal cell lines, primary endothelial cells, primary osteoblasts, and cell
lines derived from those cell types.20,86,106,107 Demonstrating SDF-1 expression in vivo,
however, has proven more difficult. Ponomaryov et al. showed human SDF-1 expression
in bone-lining osteoblasts, endothelial cells, and scattered, spindle-shaped stromal cells.20
On the other hand, Ara et al., using a transgenic mouse in which the GFP cDNA was
inserted into the SDF-1 locus, showed no colocalization of mouse SDF-1 with endothelial
marker PECAM-1.108 Using this system, little or no SDF-1 expression was detected colocalized with osteocalcin, a specific osteoblast marker, although SDF-1 expression did
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co-localize with a subset of VCAM-1 positive cells with reticular morphology termed
“CAR” cells that could be found in close proximity to endothelial cells (see above).29,109
These conflicting results are difficult to interpret, as it is difficult to tell whether replacing
exon 2 of the CXCL12 locus with a GFP expression cassette has resulted in disregulated
signaling. Further, the lack of co-expression with osteocalcin does not necessarily rule
out SDF-1 expression by osteoblasts, as osteocalcin is a late osteoblast marker expressed
only in a fraction of morphologically identifiable, functional osteoblasts.110
In sum, most studies to date report SDF-1 expression across a spectrum of nonhematopoietic cells in the bone marrow. Even so, further work is needed to resolve
whether these populations include endothelial cells or osteoblasts.

1.9 Summary
Under normal circumstances, HSC reside in bone marrow stem cell niches which
provide critical support at a molecular level to maintain their function as stem cells.
Evidence from mouse models with enhanced osteoblastogenesis suggests that osteoblasts
in particular compose a necessary part of the HSC niche. HSPC can be mobilized from
the bone marrow in response to treatment with certain mobilizing agents, the best
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characterized and most widely used of which is G-CSF. Several mechanisms likely play
a role in G-CSF-induced mobilization, including induction of bone marrow neutrophilderived proteases, downregulation of critical adhesion molecules, and disruption of SDF1/CXCR4 signaling due in part to loss of bone marrow SDF-1 (see figure 1).
However, certain questions remain. First, what is the relationship between these
several mechanisms in G-CSF-induced mobilization? Do they operate independently of
each other or do they work in tandem? Next, to what extent do other mobilizing agents
take advantage of these pathways to induce mobilization? Of note, the fall in bone
marrow SDF-1 takes place over days during G-CSF treatment, raising the possibility that
other cytokine family members—which also mobilize over a period of days—induce
mobilization in part by dropping bone marrow SDF-1. Finally, what accounts for the loss
of bone marrow SDF-1 during G-CSF treatment? What cell types make SDF-1 normally
in the bone marrow, and which of these are targeted during G-CSF treatment?
In Chapter 2 different subsets of bone marrow stromal cells will be tested for SDF-1
production and a mechanism will be proposed by which G-CSF treatment causes loss of
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bone marrow SDF-1 by targeting osteoblasts. Chapter 3 will extend these findings,
investigating whether mobilizing cytokines Flt3 ligand (Flt3L) and stem cell factor (SCF)
work in part by disrupting SDF-1/CXCR4 signaling and whether targeting of osteoblasts
represents a common motif in cytokine-induced mobilization. Further, the relative
importance of disrupted SDF-1/CXCR4 signaling vis-à-vis other pathways is tested by
examining G-CSF induced mobilization in the genetic absence of CXCR4. Finally,
Chapter 4 examines the effect of G-CSF on osteoblasts in more detail, focusing on GCSF effects on osteoblast differentiation and apoptosis. Chapter 5 synthesizes these
findings concerning cytokine effects on the stem cell niche with unpublished data
concerning HSC function after G-CSF treatment and summarizes future directions.
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CHAPTER 2

G-CSF POTENTLY INHIBITS OSTEOBLAST ACTIVITY AND
CXCL12 mRNA EXPRESSION IN THE BONE MARROW

The experiments presented in Figures 2.1-2.4 are the work of Dr. Craig Semerad, a
former post-doctoral fellow in the lab.
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2.1 ABSTRACT
There is accumulating evidence that interaction of stromal cell derived factor-1 (SDF1/CXCL12) with its cognate receptor, CXCR4, generates signals that regulate
hematopoietic progenitor cell (HPC) trafficking in the bone marrow. During
granulocyte-colony stimulating factor (G-CSF)-induced HPC mobilization, CXCL12
protein expression in the bone marrow decreases. Herein, we show that in a series of
transgenic mice carrying targeted mutations of their G-CSF receptor and displaying
markedly different G-CSF induced HPC mobilization responses, the decrease in bone
marrow CXCL12 protein expression closely correlates with the degree of HPC
mobilization. G-CSF treatment induced a decrease in bone marrow CXCL12 mRNA that
closely mirrored the fall in CXCL12 protein. Cell sorting experiments showed that
osteoblasts and to a lesser degree endothelial cells are the major sources of CXCL12
production in the bone marrow. Interestingly, osteoblast activity, as measured by
histomorphometry and osteocalcin expression, is strongly downregulated during G-CSF
treatment. However, the G-CSF receptor is not expressed on osteoblasts, accordingly GCSF had no direct effect on osteoblast function. Collectively, these data suggest a model
in which G-CSF, through an indirect mechanism, potently inhibits osteoblast activity
resulting in decreased CXCL12 expression in the bone marrow. The consequent
attenuation of CXCR4 signaling ultimately leads to HPC mobilization.
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2.2 INTRODUCTION
The majority of hematopoietic progenitor cells (HPC) reside in the bone marrow
surrounded by a complex, highly organized microenvironment. Under normal
conditions, a small number of HPC are released into the peripheral blood. Agents with
distinct cellular targets and biological activities can induce the mobilization of HPC into
blood, including hematopoietic growth factors, chemotherapeutic agents, and
chemokines.1,2 Recently, mobilized peripheral blood HPC have become the principal
cellular source for reconstitution of the hematopoietic system following myeloablative
therapy. Currently, granulocyte-colony stimulating factor (G-CSF) is the most widely
used agent to induce HPC mobilization due to its potency, predictability and safety.3
However, the mechanisms responsible for G-CSF-induced HPC mobilization have not
been defined.
We previously showed that G-CSF receptor (G-CSFR) expression on HPC is not
required for their mobilization by G-CSF, suggesting that G-CSF induces HPC
mobilization indirectly through the generation of trans-acting signals.4 The nature of the
trans-acting signal(s) that mediate G-CSF-induced HPC mobilization is unknown;
however, there is accumulating evidence suggesting that interaction of CXCL12
(stromal-derived factor-1) with its cognate receptor, CXCR4, may play an important role
in regulating G-CSF-induced HPC mobilization. CXCL12 is a CXC chemokine
constitutively produced in the bone marrow by stromal cells.5 Studies of CXCL12 or
CXCR4 deficient mice have established that these genes are necessary for the normal
migration of HPC from the fetal liver to the bone marrow and in the efficient retention of
myeloid precursors in the adult bone marrow.6,7 Moreover, treatment with AMD-3100, a
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specific antagonist of CXCR4, induces rapid and robust HPC mobilization in both
humans and mice. 8,9 Finally, we and others showed that CXCL12 protein expression in
the bone marrow is significantly decreased following G-CSF treatment.10-12.
Collectively, these data suggest a model in which disruption of CXCL12/CXCR4
signaling is a key step in G-CSF induced HPC mobilization.
The mechanism(s) mediating the G-CSF induced decrease in CXCL12 protein
expression in the bone marrow have not been defined. Previous reports suggested that
neutrophil elastase (NE) and cathepsin G (CG) might regulate CXCL12 protein
expression in the bone marrow through proteolytic cleavage of CXCL12.10,11 However,
mice genetically lacking NE and CG display normal G-CSF induced HPC mobilization,
and the expected decrease in bone marrow CXCL12 protein was observed.13 Thus, the
G-CSF-induced decrease in CXCL12 protein expression in the bone marrow does not
require these proteases. It is possible that other proteases can compensate for the loss of
NE and CG. Alternatively, non-proteolytic mechanisms may regulate CXCL12
expression in the bone marrow during G-CSF induced HPC mobilization.
In this study, we characterize G-CSF induced HPC mobilization and CXCL12
expression in the bone marrow in a series of transgenic mice carrying targeted mutations
of their G-CSFR. We provide further evidence that disruption of CXCL12/CXCR4
signaling in the bone marrow is a key step in HPC mobilization. G-CSF regulates
CXCL12 expression in the bone marrow primarily at the mRNA level. Evidence is
provided that G-CSF inhibits osteoblast number and activity through an indirect
mechanism leading to decreased CXCL12 expression in the bone marrow.
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2.3 METHODS
Mice. GEpoR, d715, and d715F deficient mice were generated, as described
previously.14-16 GEpoR, d715 and d715F mice were backcrossed 10 generations onto a
C57BL/6 background. Six to ten week-old mice were used in all studies. Mice were
housed in a specific pathogen-free environment. All experiments were approved by the
Washington University Animal Studies Committee.

Mobilization protocols. G-CSF. Recombinant human G-CSF (Amgen, Thousand Oaks,
CA) diluted in phosphate-buffered saline (PBS) with 0.1% low endotoxin bovine serum
albumin (Sigma, St. Louis MO) was administered by daily subcutaneous injection at a
dose of 250 µg/kg or 100 µg/kg per day for 5 days. Mice were analyzed 3-4 hours after
the final G-CSF dose. AMD3100. AMD3100, a generous gift from AnorMED Inc.
(British Columbia, Canada), was reconstituted in sterile PBS and administered as a single
subcutaneous injection at a dose of 5 mg/kg. Mice were analyzed 3 hours post-injection
or at the indicated times.

Peripheral Blood and Bone Marrow Analysis. Blood was obtained by retroorbital
venous plexus sampling in polypropylene tubes containing EDTA. Complete blood
counts were determined using a Hemavet automated cell counter (CDC Technologies,
Oxford, CT). Bone marrow was harvested by flushing with α-modification of eagle’s
medium (α-MEM) containing 10% fetal calf serum. Bone marrow extracellular fluid was
obtained by flushing each femur with 1 ml of ice-cold PBS without serum, and the
supernatant was harvested after centrifugation at 400 x g for 3 minutes.
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CXCL12α
α ELISA. 96-well plates were coated with 100 µl of CXCL12 capture antibody
(2 µg/ml) diluted in PBS and incubated overnight at room temperature. After incubation
for one hour at room temperature with 300 µl of blocking solution [1% bovine serum
albumin (BSA), 5% sucrose, and .05% NaN3], 100µl of sample was added to each well
and incubated for 2 hours at room temperature. After washing, 100 µl of polyclonal
biotinylated anti-human CXCL12 (250 ng/mL) in ELISA diluent (0.1% BSA, .05%
Tween 20 in Tris-buffered saline at pH7.3) was added to each well and incubated at room
temperature for 2 hours. The reaction was developed by successive incubations with 1
µg/ml horseradish peroxidase streptavidin, substrate solution, and 50 µl of 2N H2SO4 to
stop the reaction. A microplate reader set at 450 nm was used to determine optical
density with readings at 550 nm subtracted from the results. Recombinant human
CXCL12α was used to generate a standard curve. All ELISA reagents were purchased
from R&D Systems (Minneapolis, MN).

Colony-forming cell assay. Blood, bone marrow, and spleen cells were harvested from
mice using standard techniques and the number of nucleated cells in these tissues
quantified using a Hemavet automated cell counter. We plated 10-20 µl blood, 1 x 105
nucleated spleen cells, or 2.0 x 104 nucleated bone marrow cells in 2.5 ml
methylcellulose media supplemented with a cocktail of recombinant cytokines
(MethoCult 3434; Stem Cell Technologies, Vancouver, British Columbia, Canada).
Cultures were plated in duplicate and placed in a humidified chamber with 6% carbon
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dioxide (CO2) at 37° C. Colonies containing at least 50 cells were counted on day 7 of
culture.

Real-time quantitative RT-PCR. Femurs were flushed with a total of 2 ml Trizol
reagent (Invitrogen, Carlsbad, CA) followed by crushing of the remaining bone in Trizol.
RNA was isolated according to the manufacturer’s instructions and resuspended in 150 µl
RNase/DNase free water. Real-time reverse transcriptase-polymerase chain reaction
(RT-PCR) was performed using the TaqMan One-step RT-PCR Master Mix Reagents Kit
(Applied Biosystems, Foster City, CA) on a GeneAmp 5700 Sequence Detection System
(Applied Biosystems). The reaction mix consisted of 5 µl RNA, 12.5 µl RT-PCR
reaction mix, 200 nM forward primer, 200 nM reverse primer, 280 nM internal probe,
and .625 µl Multiscribe reverse transcriptase and RNase inhibitor in a total reaction
volume of 25 µl. Reactions were repeated in the absence of reverse transcriptase to
confirm that DNA contamination was not present. RNA content was normalized to
murine β-actin. PCR conditions were 48°C for 30 minutes and 95°C for 10 minutes,
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
CXCL12 forward primer: 5′-GAGCCAACGTCAAGCATCTG–3′;
CXCL12 reverse primer: 5′-CGGGTCAATGCACACTTGTC–3′;
CXCL12 dT-FAM/TAMRA probe: 5′-TCCAAACTGTGCCCTTCAGATTGTTGC–3′;
β-actin forward primer: 5′- ACCAACTGGGACGATATGGAGAAGA–3′;
β-actin reverse primer: 5′- TACGACCAGAGGCATACAGGGACAA–3′;
β-actin dT-FAM/TAMRA probe: 5′- AGCCATGTACGTAGCCATCCAGGCTG–3′.
Osteocalcin forward primer: 5'-TCTCTCTGCTCACTCTGCTGGCC-3'
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Osteocalcin reverse primer: 5'-TTTGTCAGACTCAGGGCCGC-3'
Osteocalcin dT-FAM/TAMRA probe: 5'TGCGCTCTGTCTCTCTGACCTCACAGATGCCA-3'

Cell Sorting. Bone marrow cells were recovered from the femurs and tibia of mice by
extensive flushing with 40 ml of PBS. The femurs were then infused with PBS
containing 50mg/ml of type IV collagenase (C5138, Sigma) and incubated at 370C for 15
minutes. The collagenase-treated femurs were flushed again with PBS and cells pooled
with the first flush fraction. Finally, the “empty” femurs were directly flushed with 1 ml
of Trizol, to recover RNA from cells firmly adherent to the bone matrix. The flushed
cells were incubated with fluorescein isothiocynate (FITC)-conjugated CD45 antibody
and with the following panel of phycoerythrin (PE)-conjugated lineage-restricted
antibodies: Gr-1 (granulocytes), B220 (B-lymphocytes), CD3e (T-lymphocytes), and Ter119 (erythroid cells) (all antibodies from Pharmingen, San Diego, CA). Cells were sorted
on a MoFlo high speed flow cytometer (Dako Cytomation, Fort Collins, CO). CXCL12
and β-actin mRNA were measured by quantitative real time RT-PCR. To estimate the
total CXCL12 mRNA contribution of each fraction, the number of cells in each fraction
was multiplied by the amount of CXCL12 mRNA relative to β-actin mRNA found in that
fraction. The number of cells in the Trizol-flushed fraction was estimated using β-actin
mRNA expression and was based on a standard curve showing that the level of β-actin
mRNA correlated in a linear fashion with cell number (data not shown).
Stromal cell fractionation. Femora, tibiae and iliac crests were cleaned
thoroughly to remove associated muscle tissue and then crushed in a mortar and pestle to
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release the marrow. Bone fragments were collected by filtration through a 40 µm cell
strainer (BD Biosciences, San Jose, CA) and washed extensively in PBS with 2% FCS to
remove non-adherent bone marrow cells. The bone fragments were further minced with a
scalpel and then incubated at 370C with a 3mg/ml solution of Type I collagenase
(Worthington, Lakewood NJ) in PBS for 40 minutes in a shaking waterbath. The
resulting population of bone derived cells was then depleted of residual hematopoietic
cells by incubation with a cocktail of rat anti-mouse antibodies (B220, Mac-1, Gr-1,
CD4, CD8, CD3, CD5 and Ter119) followed by incubation with anti-rat Ig coupled
Dynabeads (Dynal Biotech, Oslo Norway). Following lineage depletion, the cells were
stained with a PE-conjugated anti-CD45, FITC-conjugated anti-CD31, biotinylated antiCD51 and streptavidin coupled allophycocyanin (all from Pharmingen). The cells were
separated using a FACSDiva high speed cell sorter (BD Biosciences) into three fractions:
endothelial cells (Lin- CD45- CD31+), osteoblasts (Lin- CD45- CD31- CD51+), and
progenitor cells (Lin-, CD45+). The purity of the endothelial and osteoblast fractions was
confirmed by staining for von Willebrand factor or alkaline phosphatase, respectively
(data not shown). Sorted cells were counted and then lysed in RNAZol (Iso-Tex
Diagnostics, Friendswood, TX) or Trizol for RNA isolation and subsequent real time RTPCR analysis.

Osteoblast Culture. Murine calvarial osteoblasts were obtained using minor
modifications of published procedures.17 In brief, calvariae were removed aseptically
from 3-4 day old mice and incubated twice at 37oC for 10 minutes in PBS containing
4mM EDTA and then subjected to repeated digestion for 10 minutes at 37oC with
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200U/ml type 2 collagenase (Worthington, Lakewood, NJ) in PBS. Products of early
digestions were discarded, while later fractions (typically fractions 5-7) were collected by
centrifugation and cultured in αMEM containing 10% FCS and 1% Pen/Strep. Cells
were cultured until 80% confluent (undifferentiated osteoblasts). In some experiments,
cells were then cultured in differentiation medium (αMEM containing 10% FCS, 100
µg/ml ascorbic acid and 5mM β-glycerophosphate) for 1 week (differentiated
osteoblasts).

Histomorphometry. Osteoblasts in the bone marrow were quantified by
histomorphometry, as previously described.18 Briefly, femurs and tibiae were harvested,
fixed overnight in 10% neutral formalin, decalcified by incubating in 14% EDTA at 40C
for two weeks, and then embedded in paraffin. To ensure that osteoclasts were excluded
from the osteoblast count, deparaffinized sections were stained histochemically for
tartrate-resistant acid phosphatase (TRAP) and counterstained with hematoxylin.
Osteoblasts were counted in a blinded fashion in 4-6 200X fields per section. In some
cases, two sections 75 microns apart were taken from the same sample and osteoblast
number averaged. The number of osteoblasts per millimeter bone perimeter (N.Ob/mm)
was calculated using the OsteoMeasure Histomorphometry System (OsteoMetrics, Inc.,
Atlanta, GA).

Statistical analysis. Data are presented as mean +/- SEM or SD, as indicated in the text.
Statistical significance was assessed using a two-sided Student’s t test.
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2.4 RESULTS
2.4.1 The membrane-proximal region of the G-CSFR is sufficient to mediate HPC
mobilization. To define the region(s) of the G-CSFR required for HPC mobilization, GCSF induced HPC mobilization was characterized in a series of transgenic mice
expressing different targeted mutations of their G-CSFR (figure 1A). The d715 G-CSFR
mutation introduces a premature stop codon at nucleotide 2403, leading to truncation of
the carboxy-terminal 96 amino acids of the G-CSFR. It is representative of G-CSFR
mutations found in approximately 35% of patients with severe congenital neutropenia.19
Mice homozygous for the d715 G-CSFR mutation have normal basal hematopoiesis.15 In
the d715F G-CSFR mutant, the sole remaining tyrosine (Y704) of d715 has been mutated
to phenylalanine. STAT-3 and STAT-5 activation by the d715F G-CSFR are markedly
impaired.14 Homozygous d715F G-CSFR mutant mice display an isolated defect in
granulopoiesis.14 In the GEpoR mutation, the entire cytoplasmic (signaling) domain of
the G-CSFR is replaced with that of the erythropoietin receptor (EpoR).16 This chimeric
receptor is predicted to bind G-CSF but transmit EpoR-specific signals. Homozygous
GEpoR mice display peripheral neutropenia but have normal numbers of neutrophils in
their bone marrow.16
The G-CSFR mutant mice, all inbred on a C57BL/6 background, were treated
with G-CSF (250 µg/kg/day x 5 days) and the number of colony forming cells (CFU-C)
in the blood, spleen, and bone marrow measured (figure 1B). A similar number of CFUC was present in the bone marrow of all mice except for G-CSF treated d715 mice, where
a modest, but not statistically significant, increase was observed. Compared with wild
type mice, HPC mobilization was significantly enhanced in d715 mice. Whereas a 15fold increase from baseline in blood CFU-C was observed in wild type mice, a 32-fold
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increase was observed in d715 mice. In contrast, HPC mobilization was severely
impaired in GEpoR mice (1.7-fold increase in blood CFU-C from baseline), despite a
normal number of CFU-C in the bone marrow. d715F mice displayed an intermediate
phenotype. Though G-CSF induced a similar rise in blood and spleen CFU-C, the
number of CFU-C in the bone marrow of d715F mice was significantly increased
compared with wild type mice. Similar results were observed after treating mice with
100 µg/kg/day G-CSF for 5 days (data not shown). These data show that the membraneproximal 87 amino acids of the G-CSFR are sufficient to mediate G-CSF-induced HPC
mobilization. Moreover, these data show that the signals generated by the GEpoR are not
able to substitute for those of the G-CSFR to induce HPC mobilization.

2.4.2 Down-regulation of CXCL12α
α protein expression is a key event in G-CSF
induced HPC mobilization. Accumulating evidence suggests that CXCL12/CXCR4
signaling may be a key regulator of HPC trafficking in the bone marrow. We and others
previously showed that CXCL12α protein expression in the bone marrow decreases
during G-CSF-induced HPC mobilization.10-12 To extend these findings, we measured
CXCL12α protein levels in the bone marrow of the G-CSFR mutant mice following GCSF treatment (figure 2A). As expected, G-CSF induced a significant decrease in
CXCL12α protein expression in the bone marrow of wild type mice. Likewise, a
significant decrease in CXCL12α protein expression in the bone marrow of d715 and
d715F mice was observed. In contrast, consistent with their impaired HPC mobilization
phenotype, no significant change in CXCL12α protein expression was detected in
GEpoR mice. In fact, a highly significant correlation was observed between the degree
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of HPC mobilization and the level of CXCL12α protein in the bone marrow (p<.001,
figure 2B).
Recently, AMD3100, a selective CXCR4 antagonist capable of rapidly inducing
HPC mobilization, was described.9 To determine whether disruption of CXCR4
signaling could rescue the HPC mobilization defect in GEpoR mice, mice were treated
with AMD3100 and HPC mobilization characterized. As reported previously, in wild
type mice, treatment with a single subcutaneous injection of AMD3100 induced a rapid
increase in blood CFU-C that peaked 3 hours post-injection (figure 3A).8 Interestingly, a
similar increase in blood CFU-C was observed in GEpoR mice. Moreover, HPC
mobilization by AMD3100 was found to be normal in G-CSFR deficient mice (data not
shown). These data show that AMD3100-induced HPC mobilization does not require GCSFR signals. Collectively, these data suggest that down-regulation of CXCL12 protein
levels in the bone marrow is a key event in HPC mobilization induced by G-CSF.

2.4.3 G-CSF regulates expression of CXCL12 mRNA in the bone marrow during
HPC mobilization. Whereas previous studies have focused on the proteolytic cleavage
of CXCL12, we considered an alternative mechanism to account for the decrease in
CXCL12 protein in the bone marrow. We measured CXCL12 mRNA expression in the
bone marrow during G-CSF treatment by directly flushing isolated femurs with Trizol
reagent to ensure that RNA was recovered from all cell types in the bone marrow. Real
time RT-PCR was performed for CXCL12 and mouse β-actin, as a control for RNA
quality and content. CXCL12 mRNA progressively decreased during G-CSF treatment
reaching a nadir on day 5 when HPC mobilization is maximal and returned to normal 2
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days after discontinuing G-CSF (figure 5A). The decrease in CXCL12 mRNA closely
mirrored the decrease in CXCL12α protein expression in the bone marrow (figure 5A).
In fact, a strong correlation between CXCL12 mRNA and protein was observed (figure
5B), suggesting that CXCL12 expression is regulated primarily at an mRNA level by GCSF.

2.4.4 Osteoblasts are the major source of CXCL12 in the bone marrow. Though
controversial, current evidence suggests that CXCL12 is expressed in the bone marrow
by osteoblasts, endothelial cells, and scattered stromal cells.5,20 Moreover, a recent report
suggested that stem and progenitor cells may express CXCL12 at a low level.21 To
determine which cell type(s) in the bone marrow express CXCL12 mRNA and are
downregulated in response to G-CSF, mice were treated with G-CSF and bone marrow
cells sorted into stromal cell (CD45-negative; lineage-negative), progenitor-enriched
(CD45-positive; lineage-negative), and mature hematopoietic cell (lineage-positive)
fractions (figure 5). In addition, Trizol was directly injected into the flushed femurs to
assess the contribution of cells remaining tightly associated with the bone matrix (“bone
fraction” in figure 5B). In untreated mice, the great majority of CXCL12 mRNA was
found in the stromal cell and bone fractions (figure 5B). Furthermore, CXCL12
expression in these fractions was decreased by G-CSF-treatment. These results suggest
that stromal cells are the major source of CXCL12 in the bone marrow and are
downregulated by G-CSF treatment.
To define which stromal cell type(s) express CXCL12, the bone-adherent cell
population was further fractionated into hematopoietic progenitor, mature osteoblast, and
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endothelial cell fractions (see Methods). Low level CXCL12 mRNA was again detected
in the hematopoietic cell fraction (figure 5C). Consistent with previous studies showing
constitutive CXCL12 expression in bone marrow endothelial cells,22 a relatively high
level of CXCL12 mRNA was detected in the endothelial cell fraction. However, the
highest level of CXCL12 mRNA expression was detected in the mature osteoblast
fraction. Relative to β-actin mRNA, mature osteoblast express 9.4-fold more CXCL12
mRNA than endothelial cells. These data suggest that the majority of CXCL12 in the
BM microenvironment is produced by osteoblasts.

2.4.5 G-CSF treatment potently inhibits osteoblast activity in the bone marrow.
Surprisingly, despite the decrease in total bone marrow CXCL12 mRNA expression
(figure 5b), on a per cell basis no significant decrease in CXCL12 mRNA was detected in
osteoblasts isolated from mice following G-CSF treatment (figure 5C). These data raised
the possibility that, rather than affecting SDF-1 expression per osteoblast, G-CSF
regulated the number of osteoblasts in the bone marrow. To explore this possibility,
osteoblast number in the bone marrow was measured by histomorphometry. Indeed, after
5 days of G-CSF treatment, a striking reduction in the number of endosteal osteoblast
was observed (figure 6 A-C). To confirm this observation, the expression of osteocalcin,
a specific marker of mature osteoblasts, in the bone marrow during G-CSF treatment was
assessed (figure 6D). Notably, osteocalcin mRNA expression was sharply reduced
during G-CSF treatment; a 47 + 12 fold reduction in osteocalcin mRNA (relative to βactin mRNA) was observed in the bone marrow of G-CSF-treated mice compared with
untreated mice. Likewise, a significant decrease in serum osteocalcin protein was
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detected in G-CSF treated mice (data not shown). This latter finding is consistent with a
previous report showing that serum levels of osteocalcin decreased in patients during GCSF treatment.23 Collectively, these data provide strong evidence that G-CSF treatment
potently suppresses osteoblast activity in the bone marrow.
We next investigated whether G-CSF could directly regulate CXCL12 expression
in cultures of primary murine osteoblasts. Osteoblasts were harvested from the calvariae
of newborn mice and cultured in the presence or absence of G-CSF for 5 days. In some
experiments, the osteoblasts were first cultured for 1 week in the presence of ascorbic
acid and β-glycerophosphate to induce osteoblast differentiation. As expected, a high
level of CXCL12 protein and mRNA expression was detected in cultures of
undifferentiated and differentiated osteoblasts (figure 6E and data not shown). However,
G-CSF had no significant effect on CXCL12 expression. Moreover, no G-CSFR mRNA
was detected using a sensitive RT-PCR assay (data not shown). These data suggest that
G-CSF does not directly regulate CXCL12 expression in osteoblasts.

2.5 DISCUSSION
Clinically, G-CSF is the most widely used agent to mobilize HPC, yet the mechanisms
mediating HPC mobilization by G-CSF are poorly understood. To begin to define the
region(s) of the G-CSFR that mediate this response, we characterized HPC mobilization
by G-CSF in a series of transgenic mice carrying different targeted G-CSFR mutations.
HPC mobilization in d715 G-CSFR mice is significantly enhanced compared with wild
type mice, suggesting the presence of an inhibitory domain in the carboxy-terminal tail of
the G-CSFR. Previous studies have shown that both receptor internalization24,25 and
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activation of negative regulators of signaling (including SOC3,26 SHP-1,25 and SHIP25)
are defective with the d715 G-CSFR. Whether any of these signaling alterations is
responsible for the increased mobilization response remains to be answered.
Interestingly, the number of CFU-C in the bone marrow of G-CSF treated d715F mice is
increased compared with G-CSF treated wild type mice, despite comparable numbers of
the CFU-C in the blood and bone marrow. These observations are consistent with a
subtle defect in HPC mobilization in d715F mice. Nonetheless, these data suggest that
STAT 3 and STAT 5 activation by the G-CSFR is not absolutely required for HPC
mobilization, since their activation by the d715F G-CSFR is markedly impaired.14
Interestingly, G-CSF-induced HPC mobilization is markedly impaired in GEpoR mice,
despite a comparable (to wild type mice) expansion in myeloid cells and HPC in the bone
marrow. Thus, signals generated by the chimeric GEpoR are able to efficiently transduce
proliferative but not mobilization signals, suggesting an element of specificity in the
mobilization signaling pathways. Of note, these data clearly demonstrate that increases
in bone marrow cellularity and HPC content alone are not sufficient to induce HPC
mobilization
Accumulating evidence suggests that CXCL12/CXCR4 signaling plays a key role
in regulating HPC trafficking in the bone marrow. Mice with targeted disruptions of
CXCL12 or CXCR4 exhibit defective hematopoiesis in the bone marrow, possibly due to
the failure of HPC to migrate from the fetal liver to the bone marrow. 7,27 Moreover,
mice transplanted with CXCR4 deficient bone marrow cells show reduced engraftment
and premature release of immature myeloid cells into the blood.7,27 Elevation of
CXCL12 levels in the blood by administration of CXCL12 or by injection of an
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adenoviral vector expressing CXCL12 is associated with a significant mobilization of
HPC into the blood. 28,29 Conversely, treatment with AMD3100, a selective antagonist of
CXCR4, induces rapid and robust HPC mobilization in mice and humans.8,9 Finally, we
and others previously showed that G-CSF treatment results in a significant decrease in
CXCL12 protein levels in the bone marrow of wild type mice. 10-12 In the present study,
we show that CXCL12 protein levels in the bone marrow after G-CSF treatment strongly
correlate with HPC mobilization in the G-CSFR mutant mice. For example, the greatest
decrease in CXCL12 protein expression in the bone marrow was observed in those mice
displaying the most robust HPC mobilization, namely the d715 G-CSFR mice. Perhaps
most telling is the lack of a significant decrease in CXCL12 protein expression in the
mobilization defective GEpoR mice (figure 2). The availability of AMD3100, a selective
CXCR4 antagonist, provided the opportunity to determine whether disruption of CXCR4
signaling could rescue the mobilization defect in GEpoR mice. Indeed, AMD3100induced HPC mobilization in GEpoR mice was comparable to wild type mice.
Collectively, these data suggest that CXCL12 is an important retention signal for HPC in
the bone marrow, and the data support a model in which disruption of CXCL12/CXCR4
signaling is a key step in G-CSF-induced HPC mobilization.
It is likely that multiple mechanisms contribute to the disruption of this signaling
pathway. CD26 (dipeptidylpeptidase IV), a membrane-bound extracellular serineprotease expressed on a subset of HPC, inactivates CXCL12 through proteolytic
cleavage.30,31 Importantly, G-CSF induced HPC mobilization is defective in CD26
deficient mice or in wild type mice treated with a specific CD26 inhibitor.30,31 However,
there is no evidence showing that CD26 activity is modulated during G-CSF treatment.
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In contrast, G-CSF treatment induces the release of a number of proteases into the bone
marrow microenvironment, including NE, CG and matrix metalloproteinase-9 (MMP9).32 These proteases are able to cleave several adhesion molecules thought to play an
important role in regulating HPC trafficking in the bone marrow, including c-Kit,
VCAM-1, CXCR4, and CXCL12.10,11,33,34 In particular, NE and CG are able to cleave
and inactive CXCL12 in vitro.10,11 However, G-CSF induced HPC mobilization and
decrease in bone marrow CXCL12 protein are normal in NE x CG deficient mice.13
Thus, there must be efficient NE and CG-independent mechanisms to disrupt
CXCL12/CXCR4 signaling during G-CSF induced HPC mobilization.
As an alternative mechanism to proteolytic cleavage to regulate CXCL12
expression, we examined the effect of G-CSF treatment on the expression of CXCL12
mRNA in the bone marrow. We show that G-CSF treatment induces a decrease in bone
marrow CXCL12 mRNA that mirrors the fall in CXCL12 protein. In fact, a strong
correlation between CXCL12 protein and mRNA levels in the bone marrow was
observed. This decrease in CXCL12 mRNA is not simply due to the dilution of
CXCL12-expressing cells in the bone marrow during G-CSF treatment, since no
significant decrease in CXCL12 mRNA was observed in GEpoR mice, despite a similar
expansion of myeloid cells in the bone marrow. These data suggest that during G-CSF
induced HPC mobilization, CXCL12 expression in the bone marrow is primarily
regulated at the mRNA level.
The mechanism by which G-CSF regulates CXCL12 mRNA expression in the
bone marrow is an important unanswered question. In particular, the cell type(s) in the
bone marrow that express CXCL12 and are regulated during G-CSF treatment are
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unknown. One report suggested that CXCL12 is primarily expressed by osteoblasts,
endothelial cells, and scattered stromal cells in the mesenchyme.5 In contrast, Ara and
colleagues, using a transgenic mouse in which the green fluorescent protein gene was
inserted into the CXCL12 gene locus, reported that endothelial cells and osteoblasts in
the bone marrow did not constitutively express CXCL12.35 Finally, a recent report
suggested that a subset of hematopoietic progenitors produce a small amount of
CXCL12.21
To address this question, we quantified CXCL12 mRNA expression in sorted
bone marrow populations of mature hematopoietic cells, progenitor cells, and stromal
cells. These data confirm that progenitor cells, defined as CD45-positive lineagenegative cells, express a low level of CXCL12. Given the low level of expression and the
relative scarcity of these cells, it is unlikely that hematopoietic progenitor cells contribute
significantly to the bulk production of CXCL12 in the bone marrow. Nonetheless, it is
possible that CXCL12 expression by progenitor cells may significantly regulate the
trafficking of progenitors cells through an autocrine or paracrine mechanism; further
study is needed to address this possibility. On the other hand, bone marrow stromal cells
appear to be the major source of CXCL12 in the bone marrow. Within the stromal cell
fraction, endothelial cells and mature osteoblasts express significant CXCL12 mRNA.
Based on the high level of CXCL12 expression per cell and the relative abundance of
osteoblasts within the bone marrow stromal cell fraction, we conclude that osteoblasts are
the major source of CXCL12 in the bone marrow. Interestingly, CXCL12 mRNA
expression per osteoblast did not change during G-CSF treatment. Rather, G-CSF
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appears to regulate CXCL12 mRNA expression in the bone marrow by decreasing
osteoblast number.
There is accumulating evidence that osteoblasts play a key role in establishing and
maintaining the stem cell niche in the bone marrow.20,36,37 In addition to CXCL12,
osteoblasts express several genes thought to be important for stem cell function,
including the notch ligand Jagged-1,37 a number of hematopoietic growth factors ( e.g.,
G-CSF),38 angiopoietin,39 and N-cadherin.36 Herein, we show that G-CSF potently
inhibits mature osteoblast activity in the bone marrow. After 5 days of G-CSF treatment,
mature osteoblast number in the bone marrow was reduced at least 3-fold. Moreover,
osteocalcin mRNA expression in the bone marrow was reduced nearly 50-fold. The
magnitude of the change in osteocalcin expression compared with the change in
osteoblast number in the bone marrow suggests that G-CSF may regulate both osteoblast
number and activity. Intriguingly, patients treated long term with G-CSF develop marked
osteopenia.40 In addition, transgenic mice overexpressing G-CSF develop osteopenia.41,42
Collectively, these data raise the possibility that G-CSF, by regulating osteoblast
function, may have profound effects on the stem cell niche that ultimately contribute to
HSC mobilization.
We previously showed by analysis of bone marrow chimeras between G-CSFR
deficient and wild type mice that G-CSFR expression on bone marrow stromal cells was
neither necessary nor sufficient to mediate G-CSF-induced hematopoietic progenitor cell
mobilization.4 Consistent with this finding, in the present study we show that cultured
primary osteoblasts do not express detectable G-CSFR using a sensitive RT-PCR assay.
Moreover, G-CSF does not modulate CXCL12 expression in primary osteoblast cultures.
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Together, these data provide compelling evidence that G-CSF regulates osteoblast
CXCL12 through an indirect mechanism.
In summary, this study provides additional evidence that strongly supports a
model in which disruption of CXCL12/CXCR4 signaling is a key event in G-CSF
induced HPC mobilization. Osteoblasts appear to be the major source of CXCL12
production in the bone marrow. G-CSF treatment potently inhibits osteoblast activity in
the bone marrow, thereby reducing CXCL12 expression. These data suggest a model
(figure 7) in which G-CSF initiates the mobilization cascade by stimulating a, as yet
unidentified, G-CSFR expressing cell population in the bone marrow. These cells then
generate a trans-acting signal that suppresses osteoblast activity and, in particular,
CXCL12 expression. The consequent decrease in CXCR4 signaling in hematopoietic
progenitor cells then enhances their migration from the bone marrow, through unclear
mechanisms. A better understanding of the mechanism by which G-CSF regulates
CXCL12 mRNA expression may lead to the development of improved clinical protocols
for stem cell mobilization in patients.
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2.7 FIGURE LEGENDS
Figure 2.1 G-CSF-induced HPC mobilization in G-CSFR mutant mice. A.
Schematic of targeted G-CSF receptor mutations. Cytoplasmic tyrosines (Y) and the
conserved box 1 and box 2 motifs are indicated. In the d715F mutant, the sole remaining
tyrosine (Y704) of the G-CSFR has been mutated to phenylalanine (F). B. Tissue
distribution of HPC following G-CSF treatment. Wild type (WT) and G-CSFR mutant
mice (n=4, each) were treated with G-CSF (250 µg/kg/day) for 5 days and the number of
CFU-C in blood, spleen, and bone marrow quantified 4 hours after the final dose of GCSF. Data represent the mean +/- SD. *P < 0.05 compared with G-CSF treated wild type
mice.
Figure 2.2 CXCL12α
α protein expression in the bone marrow following G-CSF
treatment. A. G-CSFR mutant mice (n=7, each) were treated with G-CSF (100
µg/kg/day) for 5 days and the amount of CXCL12α protein in the bone marrow
extracellular fluid measured by ELISA. Data represent the mean +/- SD. *p < 0.05
compared with untreated mice of the same genotype. B. Plot of CXCL12α protein in the
bone marrow versus the log of number of CFU-C in the blood on day 5 of G-CSF
treatment (p<.001).
Figure 2.3 AMD3100 mobilization in GEpoR mice. Mice were treated with a single
subcutaneous injection of AMD3100 (5 mg/kg). The number of CFU-C in the blood was
measured over a 6 hour period (n=3-4, each time point). Data represent the mean +/- SD.
Figure 2.4 CXCL12 mRNA expression during G-CSF-induced HPC mobilization.
A. Wild type mice were treated with G-CSF (100 µg/kg/day) for 5 days followed by a 2day recovery period. The number of CFU-C in the blood (upper panel) and CXCL12
protein expression in bone marrow extracellular fluid (middle panel) were measured at
the indicated time points (n=2, each). CXCL12 mRNA expression in the bone marrow
was measured by directly flushing femurs with Trizol and performing real time RT-PCR

54

on the recovered RNA. Shown is the relative amount of CXCL12 mRNA compared with
β-actin mRNA (lower panel). B. Plot of CXCL12α protein versus CXCL12 mRNA
(r2=0.56, p<.02). C. Wild type and GEpoR mice (n=6, each) were treated with G-CSF for
5 days and CXCL12 mRNA quantified. Data represent the mean +/- SD. *p < 0.05
compared with day 0 or untreated mice.
Figure 2.5 Regulation of bone marrow stromal cell activity during G-CSF induced
HPC mobilization. A. Bone marrow cells were recovered from the femurs and tibiae of
mice by flushing and collagenase treatment and then sorted into the indicated cell
populations based on CD45 and lineage expression. Shown is a representative histogram.
B. To examine cells firmly adherent to the bone matrix, the flushed femurs were injected
with Trizol to obtain the “bone fraction”. Total CXCL12 mRNA in each cell population
was estimated by multiplying the measured CXCL12 mRNA by the cell number in each
cell fraction; the number of cells in the bone fraction was estimated based on β-actin
mRNA levels. *p<.05. C. Cells harvested from the bone fraction were sorted into the
indicated cell populations (see Methods) and CXCL12 mRNA expression relative to βactin expression measured. Data represent the mean + SEM.
Figure 2.6 G-CSF inhibits osteoblast activity in the bone marrow. Wild type mice
were treated with G-CSF (125 µg/kg twice daily for 5 days) and osteoblast activity
assessed (A-D). A&B. Representative photomicrographs showing endosteal osteoblasts
(arrows) in untreated (A) or G-CSF treated mice (B). Original magnification x 400. C.
Quantification of osteoblast number by histomorphometry. Shown are the number of
osteoblasts (N.Ob) per mm of bone perimeter. D. Bone marrow osteocalcin mRNA
expression. Total bone marrow RNA was obtained by directly flushing femurs with
Trizol. The expression of osteocalcin mRNA relative to β-actin mRNA is shown. E.
Primary osteoblasts were cultured in the presence of 100 ng/ml of G-CSF for the
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indicated time and CXCL12 mRNA quantified. Data represent the mean +/- SEM.
*p<.05.
Figure 2.7 Model of G-CSF induced HPC mobilization. Osteoblasts constitutively
produce large amounts of CXCL12, providing an important retention signal for HPC
in the bone marrow. G-CSF initiates the mobilization cascade by stimulating a
population of G-CSFR+ cells in the bone marrow. These cells, in turn, negatively
regulate osteoblast number and activity, resulting in decreased CXCL12 expression in
the bone marrow. The consequent decrease in CXCR4 signaling in HPC leads to their
migration from the bone marrow to blood.
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CHAPTER 3

SUPPRESSION OF CXCL12 PRODUCTION BY BONE MARROW
OSTEOBLASTS IS A COMMON AND CRITICAL PATHWAY FOR
CYTOKINE-INDUCED MOBILIZATION
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3.1 ABSTRACT
Numerous molecular mechanisms have been implicated in G-CSF-induced
mobilization, including the induction of bone marrow proteases, attenuation of adhesion
molecule function, and disruption of CXCL12/CXCR4 signaling in the bone marrow. In
addition, recent reports suggest that a decrease in number of CXCL12-producing
osteoblasts may play a role in this latter mechanism. However, little is known about
extent to which these mechanisms overlap or function independently of each other.
Similarly, it is unclear to what extent mobilizing cytokines besides G-CSF may share
common mechanisms. To begin to address these questions we asked whether other
mobilizing agents from the hematopoietic cytokine family operate through the
CXCL12/CXCR4 pathway. Treatment with G-CSF, Flt3L, and SCF resulted in
downregulation of CXCR4 surface expression and function on mobilized c-Kit positive,
lineage negative cells and loss of bone marrow CXCL12 protein and mRNA. Isolating
and sorting bone marrow stromal cells demonstrated that the loss of CXCL12 expression
occurred in the osteoblast—but not non-osteoblast—fraction, suggesting a central role for
osteoblasts in mediating mobilization. Next, to investigate the relationship between
various mechanisms of mobilization, we studied G-CSF-induced mobilization in mice
genetically deficient in CXCR4. G-CSF treatment led to induction of bone marrow
metalloproteinases in CXCR4 null bone marrow chimeras, but surprisingly did not
increase the number of circulating hematopoietic progenitors. In contrast, treatment with
a small molecule antagonist of adhesion molecule Very late antigen 4 (VLA-4/α4β1
integrin) doubled the number of circulating progenitors. Together, these results suggest
that CXCL12/CXCR4 signaling—featuring significant loss of CXCL12 expression by
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osteoblasts—plays a central role in cytokine-induced mobilization, and that accessory
mechanisms such as induction of proteases and downregulation of adhesion molecules
must function upstream or downstream of CXCL12/CXCR4 signaling.

66

3.2 INTRODUCTION
Under normal circumstances, hematopoiesis is regulated such that immature
hematopoietic stem and progenitor cells (HSPC) are restricted to the bone marrow and
are rarely observed in peripheral blood. Under certain circumstances, however, this
regulation is loosened and significant numbers of HSPC are released to the circulation, a
process termed “mobilization.” Mobilization can be induced pharmacologically by a
wide range of agents, including hematopoietic cytokines, chemokines, and cytotoxic
drugs. These agents mobilize HSPC to different degrees and with varying kinetics,
raising the possibility that several distinct mechanisms may exist by which mobilization
may occur. 1,2. On the other hand, as certain subsets of mobilizing agents work with
similar kinetics, the possibility remains that mobilizing agents within a molecular family
may share common mechanism of mobilization. For example, virtually all hematopoietic
cytokines studied require 5-7 days for maximum mobilization.3-7 However, common
mechanisms in cytokine-induced mobilization have yet to be identified.
The best characterized and most widely used mobilizing agent is Granulocyte-colony
stimulating factor (G-CSF).8 To date, three general mechanisms have been implicated in
G-CSF-induced mobilization (reviewed in 2,9). First, G-CSF treatment leads to
downregulation in the bone marrow of serpin family protease inhibitors as well as
upregulation of neutrophil-derived proteases neutrophil elastase (NE), cathepsin G (CG),
and metalloproteinase 9 (MMP9).10,11 The net induction of proteolysis in the bone
marrow may contribute to cell migration by facilitating degradation of extracelluar matrix
(ECM) and enhancing cleavage of key signaling molecules.12-15
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Second, G-CSF treatment is believed to disrupt mechanisms that cause bone marrow
retention of HSPC at steady state, notably the interaction between vascular cell adhesion
molecule 1 (VCAM-1) and very late antigen 4 (VLA-4/α4β1 integrin). 16-18
Finally, accumulating evidence suggests that signaling between CXCL12, a
chemokine expressed by bone marrow stroma, and its receptor CXCR4, expressed by
HSPC, plays an important role in mobilization. Irradiated mice reconstituted with
CXCR4 deficient bone marrow have at baseline a high number of circulating HSPC.19
Further, bone marrow levels of SDF-1 protein and mRNA fall during G-CSF treatment,
and mobilized HSPC express lower levels of functional CXCR4.12,13,20 Together, these
findings suggest that the disruption of CXCL12/CXCR4 signaling leads to the loss of a
key retention signal for bone marrow HSPC.
Of note, the three primary mechanisms involved in G-CSF-induced mobilization—
induction of proteases, downregulation of adhesion molecules, and CXCL12/CXCR4
disruption—likely interact at several levels. For example, upregulation of bone marrow
proteases is believed to contribute to cleavage of bone marrow CXCL12 as well as
adhesion molecules VCAM-1 and c-Kit during G-CSF-induced mobilization.12,21,22
Similarly, CXCL12 signaling contributes to HSPC adhesion to fibronectin coated plates,
suggesting that adhesion molecule disruption may occur at least in part downstream of GCSF-induced CXCL12/CXCR4 disruption in vivo.23 These findings raise the possibility,
therefore, that disruption of CXCL12/CXCR4 signaling represents the primary
mechanism by which G-CSF induces mobilization and that other mechanisms—i.e.
induction of bone marrow proteases and downregulation of adhesion molecules—operate
upstream or downstream within this pathway.
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Recently, our lab and others have reported that G-CSF treatment is associated with a
decrease in the number of mature osteoblasts in the bone marrow.20,24 As osteoblasts are
thought to be a source of CXCL12 in the bone marrow, this observation suggests that GCSF-induced loss of osteoblasts plays a role in mobilization. On the other hand, other
cell types express CXCL12, notably endothelial cells and CXCL12-abundant reticular
(CAR) cells.25,26 Indeed, several recent reports question whether osteoblasts produce
significant amounts of CXCL12, raising the possibility that the loss of osteoblasts
represents a coincidental finding unique to G-CSF treatment and does not play a role in
mobilization. 26,27
In this study we undertook to integrate recent findings concerning mechanisms of
HSPC mobilization by focusing on one well-described mechanism. Specifically, we
hypothesized that loss of osteoblast-produced CXCL12 is a common and critical
mechanism in cytokine-induced HSPC mobilization. Accordingly, we investigated
whether loss of osteoblasts was a common finding in cytokine-induced mobilization and
whether loss of osteoblasts per se could account for the overall decline in bone marrow
CXCL12. Next, we sought to determine the relative importance of disruption of CXCR4
signaling compared to other mechanisms known to be involved in mobilization—namely,
the induction of bone marrow proteases and downregulation of VCAM-1/VLA-4
interactions—by studying mobilization in mice genetically deficient in CXCR4. In this
way, we tried to define whether these separate pathways contribute to mobilization
individually or co-operate within the same mobilizing pathway.
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3.3 MATERIALS AND METHODS

Mice. Wild type (Ly5.1), CXCR4 +/- (Ly5.2, provided by K. Weilbaecher, Washington
University School of Medicine), and pOBCol2.3-GFP (gift of D. Rowe, University of
Connecticut) were on the C57BL/6 strain. Mice were housed in a specific pathogen-free
environment in accordance with the Washington University Animal Studies Committee.

Fetal Liver Transplantation. Fetal livers were harvested from embryonic day 14–16
embryos generated by setting up timed pregnancies between CXCR4+/– mice. Single-cell
suspensions were frozen in RPMI medium 1640 with 20% FCS and 20% DMSO (Sigma,
St Louis, MO). A portion of the embryo was saved to determine genotype by PCR. 6-12 week-old C57BL/6 Ly5.1 recipients were lethally irradiated by using a 137Cs source with
900 rads. Single-cell suspensions of 5x106 CXCR4–/– or WT thawed fetal liver cells
were injected into the lateral tail vein of each recipient mouse to generate CXCR4–/–
mice and WT controls.

Mobilization protocols. G-CSF, Flt-3 ligand (Flt3L), and SCF. Recombinant human
G-CSF, Flt3L, or SCF (Amgen, Thousand Oaks, CA) diluted in phosphate-buffered
saline (PBS) with 0.1% low endotoxin bovine serum albumin (Sigma, St. Louis MO) was
administered by daily subcutaneous injection at a dose of 250 µg/kg (G-CSF), 10
ug/mouse (Flt3L), or 4 ug/mouse (SCF) for 7 days. Mice were analyzed 3-4 hours after
the final cytokine dose. AMD15057. AMD15057, a generous gift from AnorMED Inc.
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(British Columbia, Canada), was reconstituted to a final concentration of .2mg/ml in
sterile 10:36:54 ethanol:propylene glycol:water and administered as a single intravenous
injection at a dose of 1 mg/kg. Mice were analyzed 3 hours post-injection.

Peripheral Blood and Bone Marrow Analysis. Blood was obtained by retroorbital
venous plexus sampling in polypropylene tubes containing EDTA. Bone marrow cells
were isolated by flushing femurs and tibias with 3-5ml cold PBS. Bone marrow
extracellular fluid was obtained by flushing each femur with 1 ml of ice-cold PBS
without serum, and the supernatant was harvested after centrifugation at 400 x g for 3
minutes.

Metalloproteinase Activity. Extracellular fluid was isolated as above. 100ul of each
sample was assayed for metalloproteinase activity using the EnzChek Gelatinase kit with
DQ Gelatin from pig skin, fluorescein conjugate substrate (Molecular Probes) according
to manufacturers’ instructions.

CXCL12 ELISA. Quantification of CXCL12 protein in bone marrow extracellular fluid
was performed using commercially available ELISA kit (R&D Systems, Minneapolis,
MN) according to manufacturers’ instructions using 50ul undiluted sample.

Colony-forming cell assay. Blood, bone marrow, and spleen cells were harvested from
mice using standard techniques and the number of nucleated cells in these tissues
quantified using a Hemavet automated cell counter. We plated 7-35 µl blood, 1 x 105
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nucleated spleen cells, or 2.0 x 104 nucleated bone marrow cells in 2.5 ml
methylcellulose media supplemented with a cocktail of recombinant cytokines
(MethoCult 3434; Stem Cell Technologies, Vancouver, British Columbia, Canada).
Cultures were plated in duplicate and placed in a humidified chamber with 6% carbon
dioxide (CO2) at 37° C. Colonies containing at least 50 cells were counted on day 7 of
culture.

Real-time quantitative RT-PCR. Femurs were flushed with a total of 2 ml Trizol
reagent (Invitrogen, Carlsbad, CA) and RNA was isolated according to the
manufacturer’s instructions and resuspended in 150 µl RNase/DNase free water.
Quantitative Real-time reverse transcriptase-polymerase chain reaction (Q-RT-PCR) was
performed using the TaqMan One-step RT-PCR Master Mix Reagents Kit (Applied
Biosystems, Foster City, CA) on a GeneAmp 7300 Sequence Detection System (Applied
Biosystems). The reaction mix consisted of 5 µl RNA, 12.5 µl RT-PCR reaction mix,
200 nM forward primer, 200 nM reverse primer, 280 nM internal probe, and .625 µl
Multiscribe reverse transcriptase and RNase inhibitor in a total reaction volume of 25 µl.
Reactions were repeated in the absence of reverse transcriptase to confirm that DNA
contamination was not present. RNA content was normalized to murine β-actin. PCR
conditions were 48°C for 30 minutes and 95°C for 10 minutes, followed by 40 cycles of
95°C for 15 seconds and 60°C for 1 minute.
CXCL12 forward primer: 5′-GAGCCAACGTCAAGCATCTG–3′;
CXCL12 reverse primer: 5′-CGGGTCAATGCACACTTGTC–3′;
CXCL12 dT-FAM/TAMRA probe: 5′-TCCAAACTGTGCCCTTCAGATTGTTGC–3′;
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β-actin forward primer: 5′- ACCAACTGGGACGATATGGAGAAGA–3′;
β-actin reverse primer: 5′- TACGACCAGAGGCATACAGGGACAA–3′;
β-actin dT-FAM/TAMRA probe: 5′- AGCCATGTACGTAGCCATCCAGGCTG–3′.

CXCR4 cell surface expression. Bone marrow and peripheral blood cells were
recovered from control and cytokine treated mice as described above. The flushed cells
were incubated with the following panel of fluorescein isothiocynate (FITC)-conjugated
lineage-restricted antibodies: Gr-1 (granulocytes), B220 (B-lymphocytes), CD3e (Tlymphocytes), and Ter-119 (erythroid cells), with allophycocyanin (APC)-conjugated
anti-c-Kit antibody and a biotinylated anti-CXCR4 antibody followed by incubation with
phycoerythrin (PE)-conjugated streptavidin (all antibodies eBiosciences, San Diego, CA,
except anti-CXCR4 from BD Pharmingen) Cells were analyze on a FACScan flow
cytometer (Becton Dickenson).

Histomorphometry. Osteoblasts in the bone marrow were quantified by
histomorphometry, as previously described.20 Briefly, femurs and tibiae were harvested,
fixed overnight in 10% neutral formalin, decalcified by incubating in 14% EDTA at 40C
for two weeks, and then embedded in paraffin. To ensure that osteoclasts were excluded
from the osteoblast count, deparaffinized sections were stained histochemically for
tartrate-resistant acid phosphatase (TRAP) and counterstained with hematoxylin.
Osteoblasts were counted in a blinded fashion in 4-6 200X fields per section. In some
cases, two sections 75 microns apart were taken from the same sample and osteoblast
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number averaged. The number of osteoblasts per millimeter bone perimeter (N.Ob/mm)
was calculated using the OsteoMeasure Histomorphometry System (OsteoMetrics, Inc.,
Atlanta, GA).

Isolation of osteoblast lineage cells by flow cytometry. Bone marrow cells were
recovered from the femurs of pOBCol2.3-GFP mice by flushing with PBS. The femurs
were then infused with PBS containing 50 mg/mL type II collagenase (Worthington
Biochemical) and incubated at 37°C for 15 minutes. The collagenase-treated femurs were
flushed again with PBS, cells pooled, and the process repeated for a total 6 digests. Pilot
experiments demonstrated that virtually all recoverable GFP positive cells were found in
these 6 digests (data not shown).
To isolate osteoblast lineage and non-osteoblast cells, pooled fractions were stained
with PE-conjugated anti-mouse CD45 and anti-mouse Ter119 antibodies (eBiosciences).
CD45-, Ter119-, GFP+ (osteoblast) and GFP- (non-osteoblast) cells were sorted directly
into TRIZOL using a MoFlo high-speed cell sorter (Dako). RNA was subsequently
isolated and Q-RT-PCR performed as above

In situ hybridization. In situ hybridization using a probe for CXCL12 was performed on
deparaffinized sections from mouse long bones as described previously, using 35S-labeled
riboprobes28 and counterstained with toluidine blue.

Statistical analysis. Data are presented as mean +/- SEM. Statistical significance was
assessed using a two-sided Student’s t test.

74

3.4 RESULTS
3.4.1 Loss of osteoblast-produced CXCL12 is a common finding in cytokineinduced mobilization. The disruption of CXCL12/CXCR4 signaling is known to be one
mechanism by which G-CSF treatment induces HSPC mobilization. Bone marrow levels
of CXCL12 protein and mRNA fall during treatment and CXCR4 surface expression on
mobilized cells is diminished, possibly through proteolytic cleavage of the extracellular
portion of the receptor.13 Of note, this process requires 5 days to reach maximum HSPC
mobilization, which mirrors the kinetics of the decline in osteoblast number.(20 and MJC,
DCL, unpublished data) As other hematopoietic cytokines—but not chemokines—
require this lengthy period to induce mobilization, we reasoned that this mechanism
might prove to be a common pathway by which cytokines induce HSPC mobilization.
Accordingly, we treated mice with two hematopoietic cytokines, Flt3 ligand (Flt3L) and
stem cell factor (SCF) as well as G-CSF. Bone marrow levels of CXCL12 protein and
mRNA were measured by ELISA and quantitative real time PCR, respectively. All three
cytokines induced a robust mobilization (Figure 1A top). Numbers of HSPC mobilized
by each agent was similar when the proliferative effect of Flt3L treatment on progenitors
is taken into account. (Figure 1A bottom) Bone marrow CXCL12 protein and mRNA
was reduced to a similar extent after mobilization with all three agents (Figure 1B).
Since some reports suggest that CXCR4 function in HSPC is attenuated with G-CSF
treatment, both CXCR4 surface expression and function was compared between HSPC
from mice treated with G-CSF, Flt3L, and SCF. First, CXCR4 surface expression was
measured by flow cytometry, gating on c-Kit positive, lineage negative (KL) cells in
mobilized blood and bone marrow. Consistent with previous reports, CXCR4 expression
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was decreased in G-CSF-mobilized versus bone marrow KL cells. A similar decrease
was noted in KL cells in Flt3L but not SCF treated peripheral blood cells (Figure 1C).
Next, CXCR4 function on mobilized peripheral HSPC was measured by comparing
migration of peripheral blood versus bone marrow CFU-C toward CXCL12 in a transwell
assay. CFU-C derived from Flt3L- or SCF-mobilized peripheral blood failed to migrate
as well as bone marrow CFU-C from these mice, suggesting that downregulation of
CXCR4 function plays a role in HSPC mobilization (Figure 1D).
Since loss of osteoblasts, a source of CXCL12 in the bone marrow, was observed with
G-CSF treatment, we hypothesized that the decrease in CXCL12 mRNA and protein
observed after Flt3L and SCF treatment resulted from a similar decrease in osteoblast
number. Standard histomorphometry performed on H&E-stained paraffin sections from
matched mice treated with G-CSF, Flt3L, and SCF confirmed a decrease in osteoblast
surface and number (Figure 1E and data not shown.)
Taken together, these findings suggest that disruption of CXCL12/CXCR4
signaling—featuring a significant loss in CXCL12-expressing osteoblasts—is a common
feature of cytokine-mediated HSPC mobilization.

3.4.2 Loss of bone marrow CXCL12 results specifically from loss of bone marrow
osteoblasts. As noted above, several cell types in the bone marrow express CXCL12,
including osteoblasts, endothelial cells, and CAR cells. Our previous results demonstrate
a loss in total bone marrow CXCL12 mRNA and protein with an associated loss of
histologically identifiable osteoblasts in mice treated with each of the cytokines tested, GCSF, Flt3L and SCF. However, as some controversy exists as to the contribution of
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osteoblast-expressed CXCL12 to total bone marrow CXCL12, we inquired whether loss
of osteoblast CXCL12 specifically was associated with cytokine induced mobilization.
First, CXCL12 in situ hybridization was performed on paraffin sections from mice
treated with G-CSF or untreated. At baseline, CXCL12 mRNA is detected both on
endosteal and trabecular bone surfaces (Figure 2A left panel, arrows) as well as in the
bone marrow proper (arrowheads). After G-CSF treatment, abundant scattered cells in
the bone marrow continue to express CXCL12, while CXCL12 expression disappears
from bone surfaces, suggesting that specifically osteoblast CXCL12 is targeted during GCSF treatment.
To confirm this finding in a more quantitative manner, we utilized transgenic mice
expressing GFP under control of a 2.3 kb fragment of the collagen I promoter. These
mice express GFP in osteoblast lineage cells, including mature osteoblasts, bone lining
cells, and osteocytes.29 As shown in representative FACS plots, which are gated on
CD45 negative, Ter119 negative cells, the stromal cell compartment can be divided into
the GFP positive osteoblast lineage and GFP negative stromal fractions, which would be
expected to include both endothelial and CAR cells (Figure 2B). As expected, the GFP
positive fraction was highly enriched for osteoblast markers osteocalcin, osteoprotegerin,
and Runx2 (data not shown). Mice were treated with G-CSF or Flt3L, osteoblasts and
stromal cells were isolated and CXCL12 mRNA was measured in each fraction. Fewer
GFP positive cells were observed in cytokine treated mice versus controls, consistent
with the loss of osteoblasts observed histologically (data not shown). Within the
remaining GFP positive population, CXCL12 mRNA was markedly reduced with respect
to beta actin. Importantly, no reduction in CXCL12 mRNA in the stromal fraction was
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noted. Together, these results suggest that loss of osteoblast-produced CXCL12 may
represent a common pathway in cytokine-induced mobilization.

3.4.3 G-CSF-induced increase in bone marrow metalloproteinase activity does not
depend on CXCR4 signaling. Next, to begin to address the relationship of
CXCL12/CXCR4 signaling disruption with other known mechanisms involved in
mobilization—induction of proteolytic microenvironment, and attenuation of integrin
function—we tested whether the upregulation of bone marrow proteolytic activity seen
during G-CSF treatment is dependent on disruption of CXCR4 signaling or is activated
independently. To this end, protease activation was tested in mice deficient in CXCR4
signaling. CXCR4 null bone marrow chimeras were generated by transplanting Ly5.2
CXCR4 knockout or wild type fetal liver cells into irradiated Ly5.1 recipients. Only
recipients that reconstituted with greater than 90% peripheral blood chimerism were
analyzed (data not shown). CXCR4 deficient and wild type chimeras were treated with
G-CSF, bone marrow plasma was isolated and tested for metalloproteinase activity by
measuring fluorescence released by cleavage of labeled gelatin. Consistent with previous
reports, G-CSF increased metalloproteinase activity in the bone marrow of treated wild
type mice (Figure 3A). A similar trend was seen in CXCR4 null chimeras (Figure 3B),
indicating that bone marrow metalloprotease activation does not depend on CXCR4
signaling.

3.4.4 G-CSF does not increase number of circulating HSPC in CXCR4 -/- chimeras.
Next we tested the relative importance of disruption of CXCR4 signaling compared to
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other mobilization pathways by measuring mobilization in CXCR4 deficient chimeras.
As mentioned above, CXCR4 deficiency at baseline leads to an elevated level of HSPC
in both peripheral blood and spleen, emphasizing the importance of this pathway in
progenitor cell trafficking (Figure 4A-B). We predicted that since G-CSF treatment
activates bone marrow proteases and disrupts function of adhesion molecules, treatment
of CXCR4 deficient chimeras would increase the number of circulating progenitors.
When treated with G-CSF, wild type controls mobilized normally. Surprisingly,
however, G-CSF treatment did not increase number of circulating progenitors in CXCR4
null chimeras (Figure 4A-B). This failure to mobilize does not reflect a deficiency in the
number of bone marrow resident CFU-C, which is the same as in controls (Figure 4C)
and is vast in comparison to the number of mobilized CFU-C.

3.4.5 Treatment with a VLA-4 antagonist mobilizes HSPC in CXCR4 -/- chimeras.
The failure of G-CSF treatment to increase the number of circulating HSPC in CXCR4 -/chimeras suggests that G-CSF mobilizes primarily through the disruption of this
signaling pathway. An alternative possibility, however, is that CXCR4-/- chimeras at
baseline already have maximally released their mobilizable pool of HSPC, despite the
large progenitor pool still present in the bone marrow.
As a control to ensure that alternative mobilization mechanisms function normally in
the CXCR4 null chimeras, we tested if activation of the integrin attenuation pathway
could increase the number of circulating progenitors in these mice. Knockout and control
chimeras were treated with AMD15057, a small molecule inhibitor of VLA-4. Chimeras
transplanted with wild type cells mobilized modestly three hours after AMD15057
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administration (Figure 5A). CXCR4 knockout chimeras mobilized to a similar extent,
suggesting that this pathway functions normally in CXCR4 deficient chimeras (Figure
5B). Taken together, these observations suggest that disruption of CXCR4 signaling is a
necessary component of G-CSF-induced mobilization.

3.5 DISCUSSION
In recent years numerous studies have outlined mechanisms by which G-CSF treatment
leads to the mobilization of HSPC. These mechanisms could be integrated in two nonmutally-exclusive models: 1) G-CSF simultaneously activates different mechanisms in
parallel, each of which contributes individually to mobilization; and 2) G-CSF activates
different mechanisms that lie within the same pathway and depend on each other for
action. Combining G-CSF treatment with AMD3100, a specific inhibitor of CXCR4
signaling, leads to increased HSPC mobilization than with G-CSF alone, lending support
to the former model.30 These results, however, are not definitive, since neither
AMD3100 nor G-CSF would be expected to completely block CXCR4 signaling. To
address this question, therefore, we studied G-CSF-induced mobilization in a model
where CXCR4 is genetically deleted from the hematopoietic compartment. Surprisingly,
G-CSF does not increase the number of circulating HSPC in this model, suggesting that
the pleiotropic mechanisms activated by G-CSF during mobilization—specifically the
activation of bone marrow proteases and the downregulation of adhesion molecules—
converge in the CXCL12/CXCR4 pathway (Figure 6).
Treatment of mice with protease inhibitors inhibits G-CSF-induced mobilization.12,13
Protease inhibition could block G-CSF-induced mobilization upstream of
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CXCL12/CXCR4 signaling disruption—namely, by decreasing clearance of bone
marrow CXCL12 or inhibiting cleavage of CXCR4 from HSPC, as is reported in the
literature—or by blocking some parallel pathway, such as inhibiting protease-dependent
tissue migration. In CXCR4 -/- chimeras, metalloproteinase activation occurs normally
with G-CSF treatment (Figure 3A-B), but fails to enhance mobilization, suggesting that
the role of protease activation in G-CSF-induced mobilization is largely upstream of the
disruption of CXCL12/CXCR4 signaling (Figure 6). It bears noting that the role of
proteases in G-CSF-induced mobilization is controversial, since the finding that protease
inhibitors inhibit mobilization contrasts with findings in mice genetically deficient in
MMP9 and neutrophil proteases, which have a normal response to G-CSF.
Inhibition of adhesion molecules is another mechanism by which G-CSF may induce
HSPC mobilization. Treatment with a VLA-4 antagonist—but not G-CSF—increases the
number of circulating HSPC in the CXCR4 -/- chimeras (Figure 4A,5B). This finding
suggests that 1) inhibiting VLA-4/VCAM-1 interaction mobilizes HSPC in a CXCR4
independent fashion; and 2) if attenuation of adhesion molecules plays a role in G-CSFinduced mobilization, this would likely occur upstream or downstream of the disruption
of CXCR4 signaling (Figure 6). Little is known about what lies downstream of CXCR4
antagonism in mobilization. CXCR4 signaling leads to cytoskeletal reorganization,
which may lead to changes in HSPC motility and adhesion to bone marrow stroma.31-33
Indeed, as noted above, incubation of HSPC with CXCL12 increases adhesion to
fibronectin in an ex vivo culture system, suggesting that modulation of adhesion
molecules may be one way that disruption of CXCL12/CXCR4 signaling enhances HSPC

81

release from the bone marrow.23 Further work will be required to elucidate the role of
adhesion molecules downstream of CXCR4 signaling.
Besides activation of bone marrow proteases, one mechanism that likely works
upstream of the disruption in CXCL12/CXCR4 signaling is the decrease in osteoblasts
observed in cytokine treatment. While the role of other CXCL12-producing cells in
maintaining supportive niches for hematopoietic stem cells remains controversial, two
findings in this work support the hypothesis that osteoblasts specifically mediate HSPC
mobilization. First, loss of osteoblasts is a common finding in G-CSF, Flt3L, and SCF
treatment. Second, after sorting bone marrow stromal cells into osteoblastic and nonosteoblast fractions we detected a loss of CXCL12 mRNA in the osteoblastic fraction
only. This finding corroborated the RNA in situ hybridization data, where G-CSF
treatment resulted in loss of CXCL12 message on endosteal surfaces but not in the bone
marrow itself. One intriguing possibility is that CXCL12 loss from the endosteum but
not from bone marrow sinusoid-associated cells results in migration of hematopoietic
cells toward the vasculature. This possibility will require a great deal more study.
Finally, it is noteworthy that several other mechanisms implicated in G-CSF-induced
mobilization may work via osteoblasts upstream of CXCL12/CXCR4 signaling.
Levesque and colleagues report that G-CSF treatment increases hypoxia in the bone
marrow,34 a process which may have adverse effects on osteoblasts. 35,36 Katayama et al
show that loss of beta adrenergic signaling inhibits G-CSF-induced HSPC mobilization
by attenuating loss of bone marrow osteoblasts.24
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To summarize, our data suggest that disruption of CXCL12/CXCR4 signaling
represents a common and critical pathway in cytokine-mediated mobilization and that
loss of osteoblast-produced CXCL12 contributes to this effect.
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3.7 FIGURE LEGENDS
Figure 3.1 Disruption of CXCL12/CXCR4 signaling is a common feature in
cytokine-induced mobilization. Mice (n=6-8 each group) were treated with G-CSF,
Flt3L, or SCF for seven days. (A) Number of CFU-C were measured in the peripheral
blood (top) and bone marrow (bottom) by methylcellulose colony-forming assay.
(B)Total bone marrow CXCL12 mRNA was measured by Q-RT-PCR (top) and CXCL12
protein in bone marrow plasma was quantified by ELISA (bottom). (C) CXCR4 surface
expression was compared between mobilized hematopoietic progenitors (PB) and bone
marrow progenitors (BM) by flow cytometry gating on c-Kit positive, lineage negative
cells in either compartment. (D) CXCR4 function in mobilized hematopoietic
progenitors (PB) and bone marrow progenitors (BM) was compared by measuring the
percent of CFU-C that migrated down a gradient of CXCL12 in a transwell assay. (E)
Bone marrow osteoblasts were enumerated in H&E stained paraffin sections using
standard histomorphometric technique. Data represents mean ± SEM. *p<.05 compared
to control, **p<.05 compared to all other groups, ***p<.001 compared to BM.
Figure 3.2 Cytokine-induced mobilization results in specific loss of osteoblast
CXCL12. Mice were treated with G-CSF, Flt3L, or SCF. (A) Representative
photomicrograph of RNA in situ from G-CSF treated (left) and untreated (right) mouse
long bone showing CXCL12 mRNA along endosteal surface (arrows) and within bone
marrow (BM, arrowheads). N=2-3 each group (B-C) Transgenic mice (n=4-5 each
group) expressing GFP in osteoblast lineage cells (pOBCol2.3-GFP mice) were treated
with cytokines, stromal cells were isolated and fractionated by flow cytometry into nonosteoblast and osteoblast fractions, and CXCL12 mRNA was measured in each fraction.
(B) representative facsplots gated on CD45 negative, Ter119 negative stromal fraction
showing GFP positive osteoblast and GFP negative non-osteoblast fraction. (C) CXCL12
mRNA in GFP positive osteoblast fraction from G-CSF-treated (left) and Flt3L-treated
(right) mice. Data represents mean ± SEM. *p<.05
Figure 3.3 G-CSF increases bone marrow metalloproteinase activity in wild type
and CXCR4 -/- chimeras. Lethally irradiated chimeras (n=4 each group) reconstituted
with CXCR4 +/+ or CXCR4 -/- fetal liver cells were treated with G-CSF and bone
marrow plasma was isolated. Metalloproteinase activity in the bone marrow plasma was
estimated by measuring cleavage of fluorescently labeled substrate and normalizing for
protein content. Shown is metalloproteinase activity for (A) CXCR4 +/+ and (B)
CXCR4 -/- chimeras. Data represents mean ± SEM. *p<.05
Figure 3.4 G-CSF treatment does not increase number of circulating progenitors in
CXCR4 -/- chimeras. CXCR4 +/+ and -/- chimeras (n=7-10 each group) were treated
with G-CSF and CFU-C were measured in (A) peripheral blood, (B) spleen, and (C) bone
marrow. Data represents mean ± SEM. *p<.05
Figure 3.5 VLA-4 antagonism increases number of circulating progenitors in
CXCR4 +/+ and CXCR4 -/- chimeras. CXCR4 +/+ and -/- chimeras (n=6-9 each
group) were treated with AMD15057, a specific VLA-4 antagonist and peripheral blood

87

CFU-C were measured in (A) CXCR4 +/+ and (B) CXCR4 -/- chimeras. Data represents
mean ± SEM. *p<.01
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CHAPTER 4

GRANULOCYTE COLONY-STIMULATING FACTOR INDUCES OSTEOBLAST
APOPTOSIS AND INHIBITS OSTEOBLAST DIFFERENTIATION
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4.1 ABSTRACT
G-CSF administration results in marked decrease in bone mineral density characterized
by increased osteoclastogenesis and loss of mature osteoblasts. Herein, we show that the
osteoblast decrease results from increased osteoblast apoptosis and inhibited osteoblast
differentiation. G-CSF acts indirectly on osteoblasts through a hematopoietic
intermediary. Finally, loss of osteoprotegerin (OPG) expression from mature osteoblasts
may contribute to the increase in osteoclasts.

Introduction: Long-term treatment with G-CSF leads to a clinically significant
osteopenia characterized by increased osteoclast activity and number. In addition, recent
reports have observed a decrease in number of mature osteoblasts during G-CSF
administration. However, neither the extent of G-CSF’s suppressive effect on the
osteoblast compartment nor its mechanisms are well understood.

Materials and methods: Transgenic mice expressing the green fluorescent protein
(GFP) under control of the rat collagen I promoter (pOBCol2.3-GFP mice) were treated
with G-CSF. Osteoblast number and apoptosis were measured by flow cytometry and
histology. Osteoblast proliferation and turnover were assessed by labeling with BrdU.
Bone marrow chimeras with G-CSF receptor deficient hematopoietic cells were
generated to test whether G-CSF acts directly on osteoblast lineage cells.

Results: G-CSF administration leads to a selective loss of endosteal and trabecular
osteoblasts; bone lining cells, osteocytes, and periosteal osteoblasts are unaffected.
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Osteoblast turnover and apoptosis are increased. G-CSF administration also leads to a
significant accumulation of osteoprogenitors in the bone marrow. The effect of G-CSF
on osteoblasts was abrogated in wild type mice transplanted with G-CSF receptor
deficient hematopoietic cells. Finally, while expression of receptor activator of
NFkappaB ligand (RANKL) in the bone marrow is relatively unaffected by G-CSF
administration, expression of the RANKL decoy receptor, OPG, is markedly decreased.

Conclusion: G-CSF administration leads to a loss mature osteoblasts in the bone
marrow through both an increase in osteoblast turnover and inhibition of osteoblast
differentiation. These effects of G-CSF on osteoblasts are mediated via a hematopoietic
intermediary. The altered ratio of RANKL to OPG expression provides a novel
mechanism by which G-CSF stimulates osteoclastigenesis.
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4.2 INTRODUCTION
Bone marrow is the normal site of both hematopoiesis and bone metabolism. As
predicted by their proximity, regulation of these tissues is highly integrated. There is
strong evidence that osteoblasts play a key role in establishing and maintaining an
appropriate microenvironment for hematopoietic stem cells. Conversely, the
hematopoietic compartment is also known to regulate bone metabolism, largely through
the production of hematopoietic cytokines [reviewed in (1), (2)].
Granulocyte-colony stimulating factor (G-CSF) is the principal cytokine
regulating granulopoiesis. Long-term treatment with G-CSF is associated with
development of clinically significant osteopenia, characterized by decreased bone mineral
density and vertebral compression fractures (3,4). In a recent study, the incidence of
osteopenia in patients with severe congenital neutropenia (SCN) treated chronically with
G-CSF was 28% (3). Similarly, long-term exposure to G-CSF in mice leads to a
decrease in cortical and trabecular bone, suggesting that it is G-CSF and not the
underlying disease that is causing osteopenia in patients with SCN. (4,5)
There is evidence that G-CSF induces osteopenia in part by stimulating osteoclast
activity. G-CSF treatment increases osteoclast number in the bone marrow of mice and
increases the level of urine deoxypyridinoline in humans. (6) Several potential
mechanisms by which G-CSF stimulates osteoclastigenesis have been advanced. G-CSF
increases the proliferation of myeloid progenitors, potentially increasing the pool of
monocytic precursors from which osteoclasts derive. (7) In addition, G-CSF has been
shown directly to augment osteoclast formation and activity in vitro. (8) Nevertheless,
the mechanisms by which G-CSF stimulates osteoclastogenesis in vivo remain undefined.
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While long-term G-CSF treatment results in increased osteoclastogenesis, recent
evidence suggests that short term G-CSF administration decreases osteoblast number and
activity (6,9,10). Our lab has shown that administration of G-CSF for 5 days in mice
results in a marked decrease in histologically identifiable osteoblasts in the bone marrow
and a corresponding decrease in osteocalcin mRNA.(10) Whether this decrease in
osteoblast number results from increased osteoblast turnover or from a defect in
osteoblast development remains unclear. A third possibility—that G-CSF induces
osteoblast quiescence—was raised in a recent report by Katayama et al., who observed a
preponderance of bone lining cells in the bone marrow of G-CSF-treated mice.(9)
In this study, we utilize transgenic mice expressing the green fluorescent protein
(GFP) under control of an osteoblast-lineage-specific promoter (pOBCol2.3-GFP mice)
to measure osteoblast turnover during G-CSF administration. We show that G-CSF
administration leads to a selective loss of mature endosteal and trabecular osteoblasts that
is secondary to both an increase in osteoblast apoptosis and inhibition of osteoblast
differentiation. Bone marrow transplantation studies show that G-CSF regulates
osteoblasts indirectly, via a hematopoietic intermediary. Finally, we show that G-CSF
treatment markedly decreases the bone marrow expression OPG, providing a novel
mechanism by which G-CSF activates osteoclasts.

4.3 MATERIALS AND METHODS.

Mice. The generation and characterization of pOBCol2.3-GFP mice, kindly provided by
David Rowe at the University of Connecticut, have been described elsewhere (11). Mice
were maintained in a pathogen-free barrier facility in accordance with Washington
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University Animal Studies Committee guidelines. 6-12 week old age and sex-matched
mice were used in all studies.

G-CSF administration. Recombinant human G-CSF, a generous gift from Amgen, was
diluted in phosphate-buffered saline (PBS) with 0.1% low endotoxin bovine serum
albumin (Sigma) and administered by twice daily subcutaneous injection at a dose of 250
µg/kg/day for the length of time indicated.

Immunohistochemistry and histomorphometry. Long bones from pOBCol2.3-GFP
and wild type mice were processed as previously described (10). Briefly, femurs and
tibiae were harvested, fixed overnight in 10% neutral formalin, decalcified by incubating
in 14% EDTA at 4°C for 7-10 days, and then embedded in paraffin. Paraffin-embedded
sections were deparaffinized, rehydrated, and antigen retrieval was performed by soaking
sections in DeCal Retrieval Solution (Biogenex) per manufacturers’ instructions. GFP
expression was assessed using a rabbit anti-GFP polyclonal antibody (Chemicon
International) and positive cells were visualized using Vector Elite ABC kit and DAB
substrate (Vector Labs) with Nuclear Fast Red counterstain (Sigma). Slides were
analyzed in a blinded fashion to determine the number of osteoblasts per millimeter bone
perimeter, osteoblast surface percent, bone lining cell surface percent, and osteocyte
number per trabecular area. Bone lining cells and osteoblasts were differentiated based
on morphology. Analysis was confined to the trabecular metaphysial region distal to the
growth plate. Osteoclasts were identified by staining sections for tartrate-resistant acid
phosphatase (TRAP). Osteoclast number and osteoclast surface were calculated based on
the presence of TRAP positive cells on trabecular surfaces.
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Osteoid surface was determined by analyzing undecalcified, methyl methacrylateembedded sections stained using the Masson trichrome technique. To determine
mineralization rate, mice were injected twice with 0.5mg calcein (Sigma) before and after
7 day G-CSF treatment. 48 hours after the second injection, calvaria were harvested,
fixed in 70% ethanol, and embedded in methyl methacrylate. Mineral apposition rate and
mineralizing surface were analyzed by fluorescent microscopy, as previously described
(12). Images were acquired with Nikon microphot SA microscope using Nikon plan 10x
and 20x objectives (Nikon Instruments) and a digital camera from Colorview Soft
Imaging System. All parameters were analyzed using OsteoMeasure Histomorphometry
System (OsteoMetrics).

Osteocalcin RNA in situ.

Osteocalcin sense and antisense 33P-labeled probes for

RNA in situ were generated using a SP6/T7 Transcription Kit (Roche) using a plasmid
generously provided by David Ornitz (Washington University). RNA in situ
hybridization was performed as previously described.(13)

Real-time quantitative RT-PCR. Femurs were flushed with 1 ml of TRIzol reagent
(Invitrogen) and RNA was isolated according to the manufacturer's instructions. Realtime reverse transcriptase polymerase chain reaction (RT-PCR) was performed as
previously described (10) using the following primers with FAM/TAMRA probes where
indicated or using SYBR green (Molecular probes).
Bglap2 (osteocalcin): 5’-TCTCTCTGCTCACTCTGCTGGCC-3’ (fwd primer); 5’TTTGTCAGACTCAGGGCCGC-3’ (rev primer); 5’TGCGCTCTGTCTCTCTGACCTCACAGATGCCA-3’ (FAM/TAMRA probe).
Tnfrsf11b (osteoprotegerin): 5’-TACCTGGAGATCGAATTCTGCTT-3’ (fwd primer);
5’-CCATCTGCACATTTTTTGCAAA-3’ (rev primer); 5’ACCGGAGCTGTCCCCCGGG-3’(FAM/TAMRA probe). Spp1 (bone sialoprotein):
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5’-ACGGCGATAGTTCCGAAGAGGAGGG-3’(fwd primer);
5’-GAGTGTGGAAAGTGTGGAGTTCTCTGCC-3’(rev primer). Akp2 (Alkaline
Phosphatase): 5’-TCCATCCTGCGCTGGGCCAAGG-3’(fwd primer);
5’-AGTCCCGATCGGCCGAGTGTGCG-3’(rev primer). Runx2:
5’-GCACTGGCGGTGCAACAAGACCC-3’(fwd primer);
5’-CGGAGTAGTTCTCATCATTCCCGGCC-3’(rev primer). Tnfsf11 (RANKL):
5’-GCAACACATTGTGGGGCCACAGC-3’(fwd primer); 5’TGGCTGGGCCTCAGGCTTGC-3’(rev primer). Actb (β Actin): 5’ACCAACTGGGACGATATGGAGAAGA-3’(fwd primer); 5’TACGACCAGAGGCATACAGGGACAA-3’(rev primer);
5’-AGCCATGTACGTAGCCATCCAGGCTG-3’(FAM/TAMRA probe).
Isolation of osteoblast lineage cells by flow cytometry. Bone marrow cells were
recovered from the femurs of pOBCol2.3-GFP mice by flushing with PBS. The femurs
were then infused with PBS containing 50 mg/mL type II collagenase (Worthington
Biochemical) and incubated at 37°C for 15 minutes. The collagenase-treated femurs were
flushed again with PBS, cells pooled, and the process repeated for a total 6 digests. Pilot
experiments demonstrated that virtually all recoverable GFP positive cells were found in
these 6 digests (data not shown).

To quantify osteoblast lineage cells, pooled fractions were stained with
allophycocyanin (APC)-conjugated anti-mouse CD45 and phycoerythrin (PE) conjugated
anti-mouse Ter119 antibodies (eBiosciences). CD45-, Ter119-, GFP+ cells were
enumerated on a FACScan flow cytometer (Becton Dickenson). In some experiments,
CD45-, Ter119-, GFP+ cells were sorted using a MoFlo high-speed cell sorter (Dako).

BrdU labeling. pOBCOL2.3-GFP mice were treated with 2mg BrdU (Sigma) daily for
14 days before G-CSF treatment. In a separate study, mice were given 2 mg of BrdU
twice daily for 5 days after G-CSF treatment. Cell fractions containing osteoblasts were
isolated as described and stained with PE-conjugated anti-Ter119 and biotinylated anti-
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CD45 coupled with Alexa 750-conjuaged streptavidin (Invitrogen). BrdU positivity was
assessed using the BD Pharmingen BrdU Flow Kit (Becton Dickenson) and an Alexa
647-conjugated anti-BrdU antibody (Invitrogen).

Activated Caspase 3 analysis. Bone marrow cells harvested from pOBCOL2.3-GFP
mice were stained with APC-conjugated anti-mouse Ter119 and biotinylated anti-mouse
CD45 (eBiosciences) coupled with Alexa 750-conjuaged streptavidin (Invitrogen). Cells
were then fixed and permeabilized with BD Cytofix/Cytoperm kit and stained with rabbit
monoclonal PE-conjugated anti-activated Caspase 3 antibody, per manufacturer’s
protocol (BD Biosciences Pharmingen).

CFU-F and CFU-Alp culture. Bone marrow was isolated from mice treated 5 days with
G-CSF and untreated controls. 3.6 million nucleated cells were plated per well in 6 well
plates. Cells were grown for four days in αMEM (Gibco) supplemented with 10% fetal
bovine syrum and Pen/Strep. After four days, media was switched to differentiation
media containing 50 mg/l ascorbic acid and 2.16mg/l Beta-glycerophosphate (Sigma),
and media was changed every 3-4 days thereafter. After 14 days culture, cells were
assayed for alkaline phosphatase positivity using a kit (Sigma), and colonies containing
more than 20 cells were scored.
Bone marrow transplantation. Wild-type (Ly5.1) and G-CSFR-/- (Ly5.2) bone marrow
cells were harvested from strain- and sex-matched mice. Cells were stained with PEconjugated mouse anti-CD45.1 or anti-CD45.2, APC-conjugated mouse anti-c-Kit, and
FITC-conjugated lineage markers anti-CD3, anti-GR1, anti-B220, and anti-Ter119
antibodies. CD45-positive, c-Kit positive, lineage negative hematopoietic progenitors
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were purified by high speed cell sorting, and 30,000-50,000 cells were injected into the
tail vein of each lethally irradiated wild type (Ly5.1) or G-CSFR-/- (Ly5.2) recipient as
previously described.(14) Two independent groups of mice received transplants; mice
were analyzed separately, and the results pooled.

Statistical analysis. Data are presented as mean ± SEM. Statistical significance was
assessed using 2-sided Student t test or two-way ANOVA (BrdU analysis).
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4.4 RESULTS
4.4.1 G-CSF treatment results in a loss of osteoblasts but not osteocytes or bone
lining cells in the bone marrow. We and others previously showed that treatment with
G-CSF leads to a loss of cuboidal osteoblasts from the bone marrow in mice.(9,10) To
further characterize this process, we first determined the kinetics of osteoblast loss during
G-CSF treatment. As shown in Figure 1A, loss of mature osteoblasts, as defined by
histomorphological criteria, was delayed, with a significant fall only seen after 5 days of
G-CSF. This effect was reversible, as osteoblast number recovered within 5 days after
stopping G-CSF.
These data were confirmed using transgenic mice expressing GFP driven by a 2.3
kb fragment of the rat type 1 collagen promoter (pOBCol2.3-GFP mice). Consistent with
a previous report (11), we observed GFP expression in these mice in mature, cuboidal
osteoblasts, morphologically flat bone lining cells, and osteocytes (Figure 1B). G-CSF
treatment resulted in a striking loss of GFP+ osteoblasts in trabecular and cortical bone.
In contrast, G-CSF had no significant effect on the number of GFP+ bone lining cells or
osteocytes (Figures 1B and 1C).
We next developed a method to analyze and sort GFP+ osteoblast-lineage cells by
flow cytometry. Briefly, hematopoietic and stromal cells were recovered from long
bones by serial collagenase digestion. Immunohistochemistry performed on long bones
after harvesting revealed efficient recovery of GFP+ cells from both control and G-CSF
treated mice (data not shown). Osteoblast lineage cells were defined as CD45- Ter119GFP+ cells; CD45+ and Ter119+ cells were excluded to improve specificity. Consistent
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with the histomorphometry data, this flow cytometry-based assay showed that the number
of osteoblast lineage cells decreased following G-CSF administration (Figure 1D, 1E).

4.4.2 G-CSF treatment selectively suppresses endosteal and trabecular but not
periosteal osteoblasts. To directly assess the effect of G-CSF treatment on bone
formation, two functional assays of osteoblast activity were measured. Consistent with
the loss of mature osteoblasts, a significant decrease in osteoid synthesis was observed in
tibias of mice treated with G-CSF (Figure 2A). Similarly, both mineral apposition rate
and total surface mineralization were decreased on the endosteal surfaces of calvaria
harvested from G-CSF treated mice (Figure 2B). However, G-CSF had no significant
effect on either parameter on the periosteal surfaces of calvaria. To test whether G-CSF
treatment preferentially targets endosteal and trabecular osteoblasts in mouse long bones
as well, we performed RNA in situ hybridization for osteocalcin mRNA. In untreated
mice, osteocalcin mRNA was readily detected on endosteal, trabecular, and periosteal
surfaces (Figure 2C, left). As expected, G-CSF treatment resulted in a significant
reduction in osteocalcin mRNA expression in endosteal and trabecular osteoblasts. In
contrast, no significant decrease in osteocalcin expression in periosteal osteoblasts after
G-CSF treatment was observed (Figure 2C, center). Collectively, these data suggest that
G-CSF selectively suppresses endosteal and trabecular osteoblasts.

4.4.3 G-CSF treatment suppresses osteoblast function through a hematopoietic cell
intermediate. The selective targeting of endosteal and trabecular osteoblasts by G-CSF
suggested the hypothesis that its effects on osteoblasts are mediated by a hematopoietic
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cell intermediary. To test this hypothesis, bone marrow chimeras were generated by
transplanting G-CSFR deficient bone marrow cells into wild type mice. Likewise,
chimeras were generated in which wild type bone marrow was transplanted in G-CSFR
deficient recipients. Since there is evidence suggesting that mesenchymal (stromal) cells
can be transplanted to recipient mice(15), we sorted hematopoietic progenitor cells
(CD45+ Kit+ lineage-) to high purity prior to transplantation. Greater than 95%
hematopoietic reconstitution with donor cells was confirmed in all chimeras 6-8 weeks
after transplantation (data not shown). Chimeric mice were then treated 5 days with GCSF and the level of bone marrow osteocalcin mRNA was measured to gauge the effect
of G-CSF on the osteoblast compartment. In chimeric mice reconstituted with G-CSFR
deficient hematopoietic cells, G-CSF treatment had no effect on osteocalcin expression
(Figure 3A). In contrast, G-CSF treatment induced a greater than 30 fold decrease in
osteocalcin mRNA in G-CSFR deficient mice reconstituted with wild type hematopoietic
cells (Figure 3B). These data show that G-CSF does not act directly on osteoblasts or
other stromal cells. Instead, G-CSF suppresses osteoblasts through activation of a
(presumably G-CSFR-positive) hematopoietic cell intermediate.

4.4.4 G-CSF treatment increases osteoblast turnover by inducing apoptosis. The
loss of mature osteoblasts during G-CSF administration could occur through three
general mechanisms: increased osteoblast turnover, decreased osteoblast production, or
induction of osteoblast quiescence (with attendant loss of GFP expression from the type I
collagen promoter). To begin to distinguish between these possibilities, we designed an
experiment to measure the turnover rate of labeled osteoblast lineage cells in the bone
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marrow. pOBCol2.3-GFP mice were treated with BrdU for 14 days prior to treatment
with G-CSF. This treatment resulted in 32% of osteoblasts lineage (GFP+) cells being
labeled with BrdU (Figure 4A). Mice were then treated with G-CSF, and the percentage
of BrdU-labeled osteoblast-lineage cells in the bone marrow was determined as a
function of time (Figure 4A). In control mice, a gradual loss of BrdU+ GFP+ cells was
observed, with a calculated half-life of 7.7 days. In mice treated with G-CSF, a more
rapid turnover of BrdU+ GFP+ cells was observed, with a half-life of 3.7 days. Of note,
after stopping G-CSF, the turnover rate of BrdU+ GFP+ cells was similar in both groups
of mice.
The increased turnover of osteoblasts in the bone marrow following G-CSF
administration suggested that G-CSF may induce osteoblast apoptosis. Indeed, regulation
of osteoblast survival is thought to be an important mechanism regulating osteoblast
number in the bone marrow (16). To test this hypothesis, we determined whether G-CSF
treatment induced apoptosis of osteoblasts. Based on the kinetics of osteoblast loss, we
focused our analyses on day 3 of G-CSF treatment. GFP+ osteoblast-lineage cells were
isolated from mice treated 3 days with G-CSF and the percentage of GFP+ cells
expressing activated caspase 3 was determined by flow cytometry (Figure 4B). In control
mice, 4.3±1.1% of GFP+ cells were apoptotic, as measured by activated caspase 3
expression. Of note, this number is within the range of reported values for osteoblast
apoptosis in untreated mice (17-21). In G-CSF treated mice, the percentage of apoptotic
cells was significantly increased (9.2 ± 0.6%, p = 0.01). These data suggest that G-CSF
treatment suppresses mature osteoblasts, in least in part, by inducing apoptosis.
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4.4.5 G-CSF administration is associated with the inhibition of osteoblast
differentiation. We next asked whether osteoblast differentiation also was impaired
following G-CSF administration. We first measured the effect of G-CSF on the
expression of a panel of genes expressed at different stages of osteoblast differentiation
(Figure 5A). G-CSF treatment resulted in a significant decrease in all of the osteoblast
genes analyzed. However, the greatest decrease in expression was observed with genes
expressed late during osteoblast maturation. Whereas a 19 fold decrease in the late
osteoblast gene Bglap2 (osteocalcin, OC) was observed, only a 1.8-fold reduction in the
pan-osteoblast lineage transcription factor Runx2 was noted.
The relative preservation of early osteoblast gene expression prompted us to
examine the effect of G-CSF on osteoblast progenitor cells in the bone marrow.
Specifically, the number of colony forming unit-fibroblast (CFU-F) and progenitor cells
capable of forming alkaline phosphatase positive colonies (CFU-ALP) was measured.
G-CSF treatment resulted in a 4.4-fold increase in CFU-F and a 12.6-fold increase in
CFU-ALP over untreated controls (Figure 5B). To determine whether this increase in
osteoprogenitors resulted in a later increase in mature osteoblasts, we extended the period
of G-CSF administration to 22 days and measured osteocalcin mRNA expression in the
bone marrow (Figure 5C). The decrease in osteocalcin mRNA expression was maximal
by 5 days of G-CSF treatment and remained suppressed throughout the 22 day treatment
period. Decreased osteoblast number was confirmed by histology (data not shown). The
prolonged loss of osteocalcin-producing osteoblasts, despite the increase in
osteoprogenitors, suggests that G-CSF administration leads to a defect in osteoblast
maturation in mice.
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As noted previously, a prior study suggested that G-CSF treatment might induce
osteoblast quiescence. This model predicts that the recovery of mature osteoblasts upon
discontinuation of G-CSF results from the reactivation of quiescent osteoblasts, rather
than the production of new osteoblasts. To test this prediction, we measured BrdU
uptake by osteoblasts during the recovery period after a five day course of G-CSF. In
control mice, 11.5± 2.6% of GFP+ osteoblast-lineage cells were labeled with BrdU at the
end of the recovery phase, reflecting the rate of recruitment of new osteoblasts during this
five-day period (Figure 5D). In contrast, 31.3± 3.6% of GFP+ cells were labeled in mice
that had received G-CSF, indicating that the rebound in osteoblast number during the
recovery phase results from recruitment of new osteoblasts rather than recovery of
quiescent osteoblasts.

4.4.6 G-CSF administration results in a decreased OPG/RANKL ratio and is
associated with a late increase in osteoclast number. Previous studies have established
that chronic treatment with G-CSF leads to increased osteoclast number and activity in
the bone marrow. (4-6,22) Though there is evidence that G-CSF can directly activate the
osteoclast lineage (8), the potent suppressive effect of G-CSF on osteoblasts suggests
another possibility. Namely, since osteoblasts contribute to the regulation of
osteoclastogenesis, the loss of osteoblasts during G-CSF treatment may secondarily
activate osteoclasts. Indeed, the kinetics of the loss in osteoblasts and increase in
osteoclasts is consistent with this possibility. While the decrease in osteoblast number
was maximal after 5 days of G-CSF treatment (Figure 1A), no increase in osteoclast
number at this time point was noted, a result consistent with previous reports (Figures 6A
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and 6B) (6,8). In fact, a significant increase in osteoclasts was not noted until after
fourteen days of G-CSF treatment.
A major mechanism by which osteoblasts regulate osteoclast number and activity
is by the regulated production of receptor activator of NF-Kappa-B ligand (RANKL,
TNFSF11) and osteoprotegerin (OPG, TNFRSF11B), a decoy receptor for RANKL.
RANKL and OPG are positive and negative regulators of osteoclasts, respectively; thus,
the relative expression of these genes is a key determinant of osteoclast activation (24).
In mice treated with G-CSF for 5 days, no change in RANKL mRNA expression in the
bone marrow was detected (Figure 6C). In contrast, a 12-fold decrease in OPG mRNA
was observed after 5 days of G-CSF treatment (Figure 6C). The ratio of RANKL to OPG
mRNA increased from 0.19 at baseline to 1.98 after 14 days of G-CSF. To verify that
the loss of OPG mRNA resulted from the loss of osteoblasts, pOBCol2.3-GFP transgenic
mice were treated with G-CSF, GFP+ osteoblast-lineage cells were isolated, and OPG and
RANKL mRNA was measured. While RANKL expression was preserved within this
fraction after G-CSF treatment, OPG mRNA was reduced 10-fold, consistent with the
loss of GFP+ mature osteoblasts (Figure 6D).

4.5 DISCUSSION
In this study, we confirm and extend our previous finding that G-CSF treatment
suppresses osteoblast number and activity. This effect appears to be specific to mature
osteoblasts, as other osteoblast-lineage cells, including osteocytes and bone lining cells,
are unperturbed. We provide evidence that G-CSF treatment increases apoptosis of
mature osteoblasts while increasing the numbers of osteoprogenitors in the bone marrow.
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Transplantation experiments show that G-CSF regulates osteoblasts in an indirect fashion
through activation of an undetermined hematopoietic cell intermediary. Finally, we show
that G-CSF treatment significantly alters the relative expression of RANKL and OPG in
the bone marrow, providing a novel mechanism by which G-CSF treatment results
osteoclast activation.
Apoptosis is thought to be one of the primary regulators of osteoblast homeostasis
in the bone marrow. There is evidence that glucocorticoid treatment and estrogen
withdrawal suppress osteoblast number through the induction of apoptosis (21,25).
Conversely, inhibition of osteoblast apoptosis during intermittent parathyroid treatment
may contribute to the bone anabolic effect seen with this treatment (20). In the present
study, we show that G-CSF treatment results in an approximately two-fold increase in the
turnover rate of BrdU-labeled osteoblast lineage cells in the bone marrow. Moreover, the
percentage of cleaved caspase 3-positive osteoblasts recovered from G-CSF treated mice
was increased two-fold compared with control mice. Together, these data suggest that GCSF regulates osteoblast number in the bone marrow, in part by, inducing osteoblast
apoptosis.
The following observations suggest that G-CSF also inhibits osteoblast
differentiation in vivo. 1) G-CSF administration results in a marked increase in
osteoprogenitors. 2) The increase in osteoprogenitors does not “rescue” the defect in
mature osteoblasts, even after prolonged (22 days) G-CSF administration. In contrast, the
increase in osteoprogenitors observed after estrogen withdrawal, which induces a greater
degree of osteoblast apoptosis, is able to restore osteoblast number to normal.(26,27) 3).
Expression of genes associated with earlier stages of osteoblast differentiation (e.g.,
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Runx2) is reduced less than genes associated with later stages (e.g., Bglap2). 4). Finally,
the rapid recovery of osteoblasts with proliferating (BrdU-labeled) cells following
cessation of G-CSF, suggests that G-CSF administration leads to the accumulation of an
expanded pool of osteoblasts precursors in the bone marrow. Collectively, these data
suggest G-CSF administration leads to a loss mature osteoblasts in the bone marrow
through both an increase in osteoblast turnover and inhibition of osteoblast
differentiation.
In addition to hematopoietic cells, there is data suggesting that the G-CSFR is
expressed on wide range of non-hematopoietic tissues including endothelial cells,
neurons, and possibly cardiomyocytes (28,29). Previous studies have shown that the GCSFR is not expressed on osteoblast cells lines or cultured primary murine calvarial
osteoblasts (9,10). Whether the G-CSFR is expressed on osteoblasts in vivo has not been
determined, therefore the possibility that G-CSF’s effects on osteoblasts are direct cannot
be excluded. In this study, we provide definitive evidence through the use of G-CSFR
deficient bone marrow chimeras that G-CSF acts indirectly to suppress osteoblasts.
Indeed, these data strongly suggest that this phenotype is dependent upon a transplantable
hematopoietic cell intermediate. Consistent with this conclusion, G-CSF treatment
preferentially targets endosteal and trabecular osteoblasts, with little effect on periosteal
osteoblasts.
The hematopoietic cell population(s) that mediate the suppressive effect of G-CSF
on osteoblasts are not known. The G-CSFR is expressed at high levels on neutrophils,
monocytes, osteoclasts, and hematopoietic progenitors. There also are reports of GCSFR expression on natural killer cells and a subset of B lymphocytes. However, the
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suppressive effect of G-CSF treatment on osteoblasts is preserved in RAG1 deficient
mice, suggesting that lymphocytes are not required for this effect (9). Studies are
underway to define the role of neutrophils, monocytes, and osteoclasts in this pathway.
The pathway leading from hematopoietic cell activation by G-CSF to osteoblast
apoptosis also remains poorly understood. In a series of elegant studies, Katayama et al
recently provided evidence that G-CSF-induced osteoblast suppression is mediated by the
sympathetic nervous system (9). Our studies of G-CSFR deficient bone marrow chimeras
strongly suggest that G-CSF does not act directly on neurons to suppress osteoblasts.
Rather, our data raise the possibility that G-CSF induced activation of hematopoietic cells
indirectly leads to activation of the sympathetic nervous system and ultimately osteoblast
apoptosis.
A consistent feature of G-CSF-induced osteopenia in both humans and mice is
osteoclast activation. Previous studies have demonstrated that G-CSF can act directly on
osteoclast precursors stimulating their differentiation in vitro into mature osteoclasts (8).
In the present study, we provide evidence for a novel mechanism by which G-CSF
treatment leads to osteoclast activation. G-CSF treatment leads to a marked decrease in
OPG expression in the bone marrow, while levels of RANKL expression remain
relatively constant. This altered ratio of OPG to RANKL expression is predicted to
increase RANK signaling in osteoclasts precursors, thereby stimulating osteoclast
production and activation. In addition to osteoblasts, RANKL and OPG are also
expressed by other stromal cells and certain lymphocyte subsets.(24) However, our data
suggest that G-CSF specifically targets the osteoblast lineage, as OPG expression was
markedly decreased after G-CSF administration in sorted GFP+ cells from pOBCol2.3-
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GFP transgenic mice. Consistent with this conclusion, G-CSF dependent
osteoclastogenesis was not observed until at least five days after the beginning of G-CSF
treatment, at which time the G-CSF-induced loss of osteoblasts was complete. This late
activation of osteoclasts by G-CSF corroborates reports from other groups (6,8) and
supports the notion that loss of OPG expression plays an important role in stimulating
osteoclastogenesis during G-CSF treatment in vivo.
In summary, G-CSF signaling through hematopoietic cells in the bone marrow
exerts powerful effects on both osteoblasts and osteoclasts, resulting in imbalance
between bone formation and resorption. It is hoped that by continuing to unravel the
pathways by which G-CSF targets bone cells, greater insight will be gained into how the
hematopoietic compartment interacts with bone cells.
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4.7 FIGURE LEGENDS
Figure 4.1 Loss of osteoblast number and function during G-CSF treatment. (A) Mice were
treated with G-CSF (250ug/kg/day) for 5 days, and the number of trabecular osteoblasts per mm of
bone perimeter was determined. (B) Immunohistochemistry showing GFP positive (brown)
osteoblasts (arrows), bone lining cells (arrowheads), and osteocytes in untreated or day 5 G-CSF
treated pOBCol2.3-GFP transgenic mouse femurs. Insets show enlargement of area enclosed by
dotted line. Original magnification 100x, scalebar=200µm. (C) Quantification of mature
osteoblasts, bone lining cells, and osteocytes in transgenic mice treated with G-CSF for 5 days or
untreated (n=4 each group). (D) Representative scatter plots showing GFP expression (lower
panels) in the stromal (CD45 negative, Ter119 negative) cell population (upper panels) isolated
from non-transgenic and pOBCol2.3-GFP mice (left and right respectively). (E) Shown is the
number of GFP+ cells recovered from the femurs of transgenic mice after treatment with G-CSF
(n=2-10 each time point). Data represent the mean ± SEM. *P<0.05, **P<0.01.

Figure 4.2 Loss of endosteal and trabecular, but not periosteal osteoblast activity
during G-CSF treatment. Osteoid and mineralization were measured in untreated mice or
mice treated for 7 days with G-CSF (n=2-3 each group). (A) Percent osteoid surface was
calculated in Masson trichrome stained tibial sections from untreated and treated wild type
mice. (B) Mineral apposition rate and percent mineralizing surface were calculated on
endosteal and periosteal surfaces from calcein-labeled calvaria. (C) Osteocalcin RNA in
situ hybridization of long bones harvested from untreated mice or mice treated for five days
with G-CSF. Shown are representative photomicrographs of 3 independent experiments.
Periosteal surfaces (arrows), endosteal surfaces (arrow heads), bone (B) and bone marrow
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(BM) are indicated. Original magnification 100x, scalebar=100µm. Data represent the
mean ± SEM. *P<0.05.

Figure 4.3 G-CSF receptor knockout bone marrow chimeras. (A) G-CSFR-/- CD45+ cKit+
Lineage- hematopoietic cells (KL) cells were transplanted into wild type recipients (n=4-5 each
group). Following hematopoietic reconstitution (6-8 weeks), chimeric mice were treated with GCSF (or left untreated), and osteocalcin mRNA expression in the bone marrow was measured by
real time RT-PCR. (B) Wild type KL cells were transplanted into irradiated G-CSFR-/- recipients
(n=6-7, each group) and analyzed in a similar fashion. Data represent the mean ± SEM. *P<0.05

Figure 4.4 Osteoblast turnover during G-CSF treatment. (A) Transgenic pOBCol2.3-GFP
mice (n=5-6, each group) were administered BrdU for four fourteen days and then either treated
for 5 days with G-CSF or left untreated. Mice were analyzed just prior to G-CSF treatment, after 5
days of G-CSF treatment, or after a 5 day recovery period (arrow heads). Shown is the percent of
GFP+ cells in the bone marrow that were labeled with BrdU. (B) Representative scatter plots
showing activated caspase 3 staining in the GFP+ cell population from untreated (left) or G-CSF
treated pOBCol2.3-GFP mice (right). (C) Shown is the percentage of GFP+ cells that express
activated caspase 3 from untreated and day 3 G-CSF-treated mice (n=4 each group). Data
represent the mean ± SEM. *P<0.05, **P<0.01.

Figure 4.5 Analysis of early osteoblast lineage cells during G-CSF treatment. (A)
Real time RT-PCR for the indicated genes was performed on total bone marrow RNA
isolated after 5 days of G-CSF treatment. RNA expression relative to β-actin mRNA was
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calculated and compared with untreated bone marrow (assigned a value of 1; n=5-12). (B)
Shown is the number of alkaline phosphatase negative (CFU-F, left) and positive (CFUAlp, right) colonies generated from the bone marrow of untreated or G-CSF treated mice
(n=5-6 each group). (C) Mice (n=2-4 each time point) were treated with G-CSF for the
indicated period up to 22 days. Mice were sacrificed at time points and analyzed for
osteocalcin mRNA by real time RT-PCR. (D) Mice (n=6, each group) were treated 5 days
with G-CSF or left untreated and then administered BrdU for five days during the recovery
period. Shown is the percent of GFP+ cells in the bone marrow that were labeled with
BrdU. Data represent the mean ± SEM. *P<0.05, **P<0.001.

Figure 4.6 Osteoclastogenesis during G-CSF treatment. (A and B) Wild type mice
(n=2-6 each group) were treated with G-CSF for the indicated time or left untreated.
Osteoclast number (A) and surface (B) were estimated by enumerating TRAP positive cells
in paraffin embedded sections of mouse long bones. (C) RANKL and OPG mRNA
expression in the bone marrow of untreated or 5-day G-CSF treated mice (n=5-8 each
group) was measured by real time RT-PCR. (D) GFP+ cells were sorted from G-CSFtreated pOBCol2.3-GFP mice. RANKL and OPG mRNA was measured within this
fraction. Data represent the mean ± SEM. *P<0.05, **P<.01
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Figure 4.2
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Figure 4.3
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CHAPTER 5

SUMMARY AND FUTURE DIRECTIONS
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The major goal of this thesis was to clarify the role of CXCL12/CXCR4 signaling in
cytokine-induced mobilization and refine our understanding of how CXCL12 expression
decreases in the bone marrow during G-CSF treatment. Unexpectedly, we uncovered a
role for osteoblasts in regulating HSPC trafficking during cytokine treatment and have
demonstrated a role for the hematopoietic compartment in regulating bone homeostasis
by mediating osteoblast apoptosis and differentiation. While we have observed this
phenomenon only in the rather specialized and non-physiologic setting of cytokineinduced mobilization, it is possible that further study will reveal a critical and reciprocal
dependence between the hematopoietic and osteoblast compartments. Finally, recent
reports that osteoblasts play a key role in maintaining the hematopoietic stem cell niche
raise the possibility that cytokine treatment leads to mobilization in part by disrupting the
stem cell niche.

5.1 Osteoblasts are a major source of bone marrow CXCL12 and decrease in
number with G-CSF treatment. In Chapter 2 of the thesis, we investigate the decrease
in bone marrow expression of CXCL12 observed during G-CSF treatment by comparing
CXCL12 expression in different bone marrow populations. To this end, a novel method
of isolating stromal cells, including bone-adherent osteoblasts, by subjecting mouse
bones to serial collagenase digests was developed. Isolated cells were fractionated into
hematopoietic, osteoblast, endothelial, and primitive mesenchymal progenitor fractions
by high speed flow cytometry-based cell sorting. It was demonstrated that the osteoblast
fraction was highly enriched for CXCL12 expression, suggesting that osteoblasts may
play an important role in HSPC mobilization. Therefore, osteoblast number was

128

compared in mice treated with G-CSF or left untreated, and a roughly 50% reduction in
the number of histologically identifiable endosteal and trabecular osteoblasts was
observed. This finding corroborates previous data by Takamatsu et al who found that
serum osteocalcin decreases in humans treated with G-CSF.1 The loss of osteoblasts
combined with the observation that osteoblasts represent a major source of bone marrow
CXCL12 raise the possibility that the decrease in osteoblasts may play an important role
in mobilization.

5.2 Loss of osteoblast-derived CXCL12 plays a critical role in cytokine-induced
mobilization. Chapter 3 furthers these studies on the role of osteoblasts in mobilization
by providing three observations. First, loss of osteoblasts and disruption of
CXCL12/CXCR4 signaling is a common finding in mobilization induced by G-CSF,
Flt3L, and SCF. Second, the decrease in bone marrow CXCL12 in cytokine-induced
mobilization is attributable specifically to the loss of osteoblast-produced CXCL12.
Third, disruption of CXCL12/CXCR4 signaling is the principle pathway by which GCSF induces mobilization. This latter finding was highlighted in experiments that
showing that an antagonist of VLA-4 sigaling—but not G-CSF—increased the number of
circulating HSPC in the genetic absence of CXCR4 in hematopoietic cells. These data
strengthen the association between decreased osteoblast number and HSPC mobilization.

5.3 G-CSF treatment increases osteoblast apoptosis and blocks differentiation
through a hematopoietic intermediary. Chapter 4 of the thesis investigates in more
detail the effect that G-CSF has on osteoblast number and function. The kinetics of
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osteoblast loss were found to mirror mobilization, with no osteoblast loss detected until
day 4 of treatment. Both osteoid formation and bone mineralization was reduced by GCSF treatment, consistent with the loss of osteoblasts, and mRNA expression of
osteoblast markers Runx2, bone sialoprotein, alkaline phosphatase, and osteocalcin were
sharply decreased. The loss of osteoblasts does not result from failure of osteoprogenitor
commitment, as the number of alkaline phosphatase positive CFU-F was strikingly
increased with G-CSF treatment. Instead, by making use of transgenic mice expressing
GFP in osteoblast lineage cells (pOBCol2.3-GFP mice) we determined that the half life
of labeled osteoblasts decreased by half during G-CSF treatment. This decrease may be
due to accelerated apoptosis, as there was a roughly 2-fold increase in the percent of
activated caspase 3 positive osteoblasts in G-CSF treated mice. Interestingly, despite the
increase in osteoprogenitor number, osteoblast number and osteocalcin expression never
recover with prolonged G-CSF treatment (up to 22 days) suggesting that G-CSF blocks
osteoblast development. Finally, we generated bone marrow chimeras by transplanting
G-CSF receptor deficient hematopoietic cells into wild type mice and administered GCSF. These mice failed to mobilize and had no decrease in osteocalcin expression,
showing that the effect of G-CSF on osteoblasts is indirect and requires signaling through
the hematopoietic compartment. The nature of these signals and the identification of the
hematopoietic cell type(s) involved will be a major goal of our lab in the future.

5.4 Bone marrow monocytes may play a key role in supporting osteoblasts. As a
first step toward understanding the molecular pathways by which G-CSF regulates
osteoblasts, we hope to identify the hematopoietic cell type or types that are required for
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G-CSF-induced suppression of osteoblasts. Hematopoietic cell types likely to regulate
osteoblasts include lymphocytes and monocyte/osteoclast lineage cells. However, mice
deficient in lymphocytes due to the Rag2 gene mobilize normally, making it unlikely that
lymphocytes mediate this effect. (2 and D.C.L. unpublished data) Therefore we
hypothesize that osteoblast development and apoptosis are mediated by monocyte lineage
cells in the bone marrow during G-CSF treatment. The first approach we are using to
address this hypothesis is to generate transgenic mice that express the G-CSF receptor
under control of the human CD68 promoter.3,4 This promoter is expected to direct GCSF receptor expression in monocyte and macrophage lineages only, and when crossed
with our G-CSF receptor deficient mice would generate offspring where the G-CSF
receptor expression is restricted to monocytes and macrophages. These mice will then
be tested for response to G-CSF.
The second approach to testing the hypothesis that bone marrow monocytes mediate
G-CSF effects on osteoblasts has been to administer G-CSF to transgenic mice whose
monocyte lineage cells have been ablated by a monocyte-expressed suicide gene. Socalled Mafia (“Macrophage Fas-induced Apoptosis”) mice lose monocyte lineage cells
when treated 5 days with a synthetic suicide receptor ligand, referred to as the
“dimerizer.” 5,6 Mafia mice treated five days with dimerizer mobilize HSPC to peripheral
blood, an effect accompanied by a striking loss of osteocalcin expression and identifiable
osteoblasts (Figure 5.1B-C) with no discernable effect on osteoclasts or osteoprogenitors
(not shown). These results suggested two possibilities. First, the loss of monocytes may
result in the loss of a factor that osteoblasts need for survival. Alternately, the loss of
monocytes may result in non-specific toxicity in osteoblasts. To help distinguish
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between these two possibilities, mixed chimeras were generated by transplanting wild
type and Mafia bone marrow mixed 1:1 into lethally irradiated hosts. If loss of
monocytes removes a factor that osteoblasts need for survival, it may be supposed that in
the absence of one half the normal complement of monocytes, most osteoblasts will
survive. On the other hand, if loss of monocytes causes release of a toxic factor, loss of
even one half of total monocytes would cause measurable toxicity. In 1:1 mixed wild
type to Mafia chimeras, dimerizer treatment resulted in no significant loss in osteocalcin
expression, compared to 760-fold reduction in dimerizer-treated Mafia mice (Figure
5.1D). These results suggest that bone marrow monocytes may play a role in steady state
maintenance of osteoblasts. Further work will be required both to confirm these findings
and to identify a putative monocyte-derived factor that supports osteoblasts.

5.5 Loss of osteoblasts during G-CSF treatment severely compromises
hematopoietic stem cell function. As osteoblasts play a critical role in maintaining the
hematopoietic stem cell (HSC) pool, we have performed some preliminary experiments
assessing the function of HSC after G-CSF treatment. Repopulating function of HSC
from G-CSF treated mice is markedly reduced compared to untreated HSC in a
competitive repopulation assay, which is the gold standard measure of stem cell
function.7 This effect is seen in both primary and secondary transplants (Figure 2A-B)
and is present even when bone marrow from treated animals is injected intrafemorally,
suggesting that it does not result from an artifactual failure to home to the bone marrow
of irradiated recipients (Figure 2C). Further work on characterizing the precise molecular
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defect in HSC from G-CSF treated mice is being continued by Priya Gopalan, an
Oncology Fellow in the lab.

5.6 Conclusion. The studies described in this thesis shed light on molecular
underpinnings of HSPC both by demonstrating the interdependence of previously
described mechanisms and by revealing a novel mechanism involved in mobilization,
cytokine-induced loss of osteoblasts. When this work was begun, the prevailing model
for HSPC mobilization centered on the role of proteases, upregulated by G-CSF
treatment, which work through pathways organized in parallel (Figure 5.3A). Proteolytic
cleavage of integrins, hyaluronic acid, c-Kit, and CXCL12 all contribute to mobilization
in this model. The work presented here, however, suggests a somewhat different model
(Figure 5.3B). The finding that G-CSF treatment leads to loss of bone marrow
osteoblasts and CXCL12 mRNA (Chapter 1) raises the possibility that protease activation
is not necessary for clearance of CXCL12. That G-CSF does not increase mobilization in
the absence of CXCR4 signaling (Chapter 2) suggests that this one pathway is sufficient
to mediate HSPC mobilization during G-CSF treatment. In this revised model, loss of
osteoblasts—an indirect effect of G-CSF treatment mediated through the hematopoietic
system—is upstream of CXCL12/CXCR4 disruption, and future research will focus on
what lies upstream and downstream of this signaling axis.
It bears noting that the implications of these findings extend beyond the field of HSPC
mobilization. First, the loss of osteoblasts results in a significant, although temporary,
loss in HSC repopulation ability. Better understanding G-CSF-induced osteoblast
depletion and its downstream effects on HSC may lead to important discoveries about
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HSC biology and factors that sustain HSC in their bone marrow niche. Second,
identifying pathways by which the hematopoietic compartment regulates osteoblast
apoptosis and differentiation may improve our understanding of bone homeostasis and
how the hematopoietic compartment and the bone compartment regulate each other’s
function. Thus G-CSF-induced mobilization may prove to be a useful platform for
improving our understanding of wider biological processes.
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5.8 FIGURE LEGENDS
Figure 5.1. Monocytes may play a key role in supporting osteoblast survival in vivo.
Mafia transgenic mice (n=5 each group) were treated with dimerizer or vehicle to induce
monocyte death. (A) HSPC mobilization as measured by number peripheral blood CFUC. (B) Total bone marrow osteocalcin mRNA as measured by Q-RT-PCR. (C)
Representative photomicrograph showing TRAP stained paraffin sections from long
bones of vehicle treated (left) or dimerizer treated (right) mice. Osteoblasts are difficult
to find in the right panel, although red-staining osteoclasts are abundant. (D) Wile type
and Mafia bone marrow was mixed at a 1:1 ratio and transplanted into irradiated
recipients. Resulting mixed chimeras were treated 5 days with dimerizer or vehicle,
RNA was isolated from long bones and osteocalcin mRNA was measured. The
difference was not statistically significant. Data represent mean ± SEM. *p<.05
Figure 5.2. G-CSF treatment causes loss of hematopoietic stem cell function. Ly5.1
mice were treated 7d with G-CSF or left untreated then injected with an equal number of
unmanipulated Ly5.2 cells into lethally irradiated Ly5.1/5.2 hosts (n=5 each group).
Shown is peripheral blood chimerism of Ly5.1 test cells eight months up to eight months
post transplant in mice that received (A) intravenous or (B) intrafemoral transplants. (C)
After 8 months, primary recipients were harvested and transplanted into irradiated
secondary recipients who were subsequently analyzed 6 weeks later for peripheral blood
chimerism in B220, Gr-1, and CD3 lineages. Data represent mean ± SEM. *p<.01
Figure 5.3. Two competing models for G-CSF-induced HSPC mobilization. (A)
Previous reports suggested a model where a variety of adhesive or chemotactic
interactions worked in parallel to mediate HSC retention in the bone marrow (left). In
this model, these interactions are attenuated by proteolytic cleavage upon G-CSF
treatment. (B) Model of G-CSF-induced mobilization as suggested by experiments
presented here. At steady state monocytes produce trophic factor to maintain osteoblast
compartment. G-CSF acts on monocytes to downregulate trophic factor, resulting in loss
of osteoblasts. Loss of osteoblast CXCL12 expression in this model is sufficient to lead
to mobilization.
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